

C t t

P

董事、监事及高级管理人员

一、董事

（一）现任董事

M. GUAN W (C 董 监 事)
M. WANG L 董 监 事

（二）独立董事

M. QIN H 董 监 事
M. LI C 董 监 事

（三）非独立董事

M. ZHONG W 董 监 事
M. LIU N 董 监 事

（四）高级管理人员

M. ZHONG W (C 董 监 事)
M. LIU N 董 监 事
M. LI C 董 监 事

（五）监事

M. LIU N (C 董 监 事)
M. GUAN W 董 监 事

（六）高级管理人员

M. ZHONG W 董 监 事
M. LIU N 董 监 事

二、高级管理人员

M. GUAN W (C 董 监 事)
M. ZHONG W 董 监 事
M. QIN H 董 监 事

（一）现任高级管理人员

M. XU N (C 董 监 事)
M. XU Y 董 监 事
M. XIE T 董 监 事
M. QIAN C 董 监 事

（二）非高级管理人员

M. WANG J 董 监 事
M. WONG W 董 监 事

（三）高级管理人员

M. GUAN W 董 监 事
M. WONG W 董 监 事

（四）监事

BDO C S L P C P A LLP

（五）高级管理人员

C C

（六）高级管理人员

PRC

S R
H R D
W , Z
PRC

CONTACT INFORMATION

Parent Company: Wenzhou Kangning Hospital Co., Ltd.

40/F, Daxue Road, Fuyuan District, Wenzhou

248 Qianjiang Road, Ershu District, Wenzhou

Wenzhou

China

Headquarters: Wenzhou Kangning Hospital Co., Ltd.

China Wenzhou Kangning Hospital Co., Ltd. S. 1712-1716, 17 F

S. 1712-1716, 17 F

H. 1712-1716, 17 F

183 Qianjiang Road, Ershu District, Wenzhou

Wenzhou

China

S. 1712-1716, 17 F

2120

China Wenzhou Kangning Hospital Co., Ltd. S. 1712-1716, 17 F

S. 1712-1716, 17 F

Headquarters: Wenzhou Kangning Hospital Co., Ltd.

Tel: (86) 577 8877 1689

Fax: (86) 577 8878 9117

E-mail: @

五、合并现金流量表

合并现金流量表

	2022 MB'000	2021 RMB'000 (人民币)	2020 RMB'000 (人民币)	2019 RMB'000	2018 RMB'000
经营活动产生的现金流量	1,484,903	1,297,430	989,012	860,692	745,972
投资活动产生的现金流量	15,605	95,691	83,509	55,523	106,910
筹资活动产生的现金流量	26,574	54,831	30,662	-17,295	-31,941
汇率变动对现金及现金等价物的影响	-10,969	40,860	52,847	38,228	74,969
现金及现金等价物净增加额	-24,221	44,036	64,961	57,289	80,596
期初现金及现金等价物余额	13,252	-3,176	-12,114	-19,061	-5,627

	2022 MB'000	2021 RMB'000 (人民币)	2020 RMB'000 (人民币)	2019 RMB'000	2018 RMB'000
经营活动产生的现金流量	2,637,787	2,377,955	2,161,262	2,117,352	1,840,724
投资活动产生的现金流量	1,311,885	1,097,676	946,349	855,843	635,451
筹资活动产生的现金流量	1,325,903	1,280,279	1,214,913	1,261,509	1,205,273
汇率变动对现金及现金等价物的影响	1,201,585	1,208,264	1,122,248	1,164,484	1,120,995
现金及现金等价物净增加额	124,318	72,015	92,665	97,025	84,278

注：报告期内，公司合并现金流量表各项目金额与母公司现金流量表各项目金额存在差异，主要系合并范围内子公司现金流量表各项目金额与母公司现金流量表各项目金额存在差异所致。

D
1,107
I
G
-
COVID-19

D
R
P
G
-
COVID-19

I
M
COVID-19

12,172
3,266

I 2022, G RMB1,484.9 , 14.4% 2021, RMB1,366.8 , 13.6% 2021. L G G , Z P . T G 27 2021 29 2022 (8,728 2021 9,688 2022. W , G , , G ,

I 2022, G
G
T
,

T
L
K
G
!

F    B  D , I                         

GUAN W

C 4 4

Zhang, PRC

A 28, 2023

O O 25, 16, C C C C P S C H

M t D , A y

[illegible]

O S 9, 2021, S C H C N H R A P (2021-2025), 100

O J 10, 2022, 21 N D R C (NDRC) N

O A 27, 2022, G O S C 14 F -Y P N H ,
 ,
 ,
 ,
 ,
 ,
 ,
 .

O D 14, 2022, C C C P C S C O
S P E D D (2022-2035), C S C O

M 2022 D 2022 A

B R

I 2022, C H C I . W , G , - , G ,

T G , 2022. D R P , G , W K H , G K H , Q K H , Y K H Y K H . I , G K H , Q K H Y K H , I , G , P Y H , C ,

Mit D. A. y.

O, **G**, **I** 2022,
G 1,107 , 12,172 ,
3.266 . I ,
G -
COVID-19 **COVID-19**

I 2022, G

B H

[illegible]

I 2022, G Z P C R C P M D
Z P B N C R C M D , -
N N S F C T G
I S T C B D P A , D D
T Z P
A , G NSSI (N -S
S -I A), L G P (D ADHD D T), L T ,
K P Z P ,

M 2022 12 31 A

B O

T G , 2022 12 31 2021 12 31 :

() R 2020 2022, 61.4%, 68.6% 69.3% . I G , G ,

() R . U PRC, . W G , , ;

Management Discussion and Analysis

Financial Results

During the year, the Company's total revenue was RMB1,484.9 million, an increase of 14.4% compared with 2021. Among them, the revenue of the main business was RMB1,366.8 million, an increase of 13.6% compared with 2021. The revenue of the other business was RMB118.1 million, an increase of 23.9% (2021: 25.4%). The Company's total operating costs were RMB352.9 million, an increase of 7.3% compared with 2021. The Company's total operating profit was RMB-24.2 million, a decrease of 100% compared with 2021. The Company's total profit was RMB41.1 million, an increase of 17.2% compared with 2021. The Company's total profit after tax was RMB227.2 million, an increase of 17.2% compared with 2021.

Revenue and Cost

The Company's total revenue was RMB1,484.9 million, an increase of 14.4% compared with 2021. Among them, the revenue of the main business was RMB1,366.8 million, an increase of 13.6% compared with 2021. The revenue of the other business was RMB118.1 million, an increase of 23.9% (2021: 25.4%).

The Company's total operating costs were RMB352.9 million, an increase of 7.3% compared with 2021.

Financial Results Data 31,
2022 2021
(MB'000) (RMB'000)

F R P , G ' B R RMB1,425.0 , 15.9%
2021, . D R P , W
RMB43.5 , 2021. T G 2023. D R
P , RMB14.6 , RMB12.6 2021,
- .

M t D A

T
a
a
B
R
,
a
G

F
b
y
D
31,
2022
2021
(
MB'000)
(RMB'000)

t t h h		
B R	1,119,887	962,408
C	770,287	658,194
G	349,600	304,214
h , t		
B R	305,118	267,588
C	269,828	238,918
G	35,290	28,670
B , f h t	1,425,005	1,229,996
C	1,040,115	897,112
G	384,890	332,884

D
R
P
,
B
R
G
RMB1,425.0
,

Mit D. A. y.

D R P , B R RMB1,218.3 ,
15.6% 2021, G ,
13.0%, - Q K H , Y K
H , T K H , W N H , W C H , P C Y
H , Y Y H J S H ; ()
G , 2.4%. T B R B R
85.5% (2021: 85.7%).

D R P , B R RMB206.7 , 17.2% 2021, 30.9% 10.5%. T 14.5% (2021: 14.3%).

D R P , B R 16.4% 2021, 78.6% (2021: 78.2%)
B R ; B R 14.0%
2021, 21.4% (2021: 21.8%) B R , :
B R 12.8% (2021: 13.8%),
B R 71.9% (2021: 69.3%).

C G ,

T G :

	February 28, 2022	December 31, 2021
	2022	2021
	(RMB'000)	(RMB'000)
Prepaid expenses and other receivables	339,777	310,090
Employee receivables	390,107	321,207
Due from related parties	33,584	42,283
Due from subsidiaries	99,553	75,386
Contract assets	63,747	53,470
Others	27,588	25,595
Others	85,759	69,081
Contract receivables, net of allowance for credit losses	1,040,115	897,112

M 2022 12 31 A

D R P , G , RMB1,040.1 , 15.9% 2021. I : () 9.6% ; () 21.5% 32.1% 2021.

F , 32.7% (2021: 34.6%). T 37.5% (2021: 35.8%). T 12.8% (2021: 13.1%).

R T G , D R P , G RMB110.0 , RMB85.5 (2021: RMB51.6).

O T G , D R P , RMB8.1 (2021: RMB23.6), S Y H .

G P G P M D R P , G RMB352.9 , 7.3% 2021. T RMB326.7 , 6.9% 2021. T :

	F b y 2022	D 31, 2021
T 27.4%	27.4%	29.6%
P 11.6%	11.6%	10.7%
O h t 23.9%	23.9%	25.4%
P 22.2%	22.2%	24.7%
C t f t 23.8%	23.8%	25.4%

Management Discussion and Analysis

During the reporting period, the Company's operating income increased by 23.8% (2021: 25.4%), and the net profit attributable to shareholders increased by 2.2% (2021: 25.4%). The Company's operating income in 2021 was RMB43.6 million.

Operating Income

During the reporting period, the Company's operating income was RMB5.0 million (2021: RMB5.8 million).

Operating Expenses

During the reporting period, the Company's operating expenses were RMB15.0 million (2021: RMB10.3 million). The Company's operating expenses increased by 1.1% (2021: 0.9%).

Operating Profit

During the reporting period, the Company's operating profit was RMB1.0 million (2021: RMB1.0 million). The Company's operating profit decreased by 1.1% (2021: 0.9%).

	For the reporting period ended December 31, 2022 (in MB'000)	2021 (RMB'000)
Operating income	111,252	100,510
Operating expenses	24,761	22,117
Operating profit	29,187	13,014
Operating loss	4,359	2,835
Operating profit	36,328	37,896
Operating profit	205,887	176,372

During the reporting period, the Company's operating profit was RMB205.9 million (2021: RMB13.5 million). The Company's operating profit increased by 16.7% (2021: 25.4%). The Company's operating profit decreased by 15.1% (2021: 14.7%).

Management Discussion and Analysis

Reported Period: December 31, 2022 Reported Period: December 31, 2021 Unit: RMB'000		2022	2021
		(RMB'000)	(RMB'000)
Cash and cash equivalents		18,899	16,487
Receivables		9,803	8,059
Prepaid expenses		4,053	3,114
Other		273	302
Total		33,028	27,962
December 31, 2022 December 31, 2021		RMB33.0	(2021: RMB27.962)

Management Discussion and Analysis

During the reporting period, the company's operating income was RMB44.3 million, an increase of 51.1% compared with the same period in 2021, and the net profit was RMB6.7 million, an increase of 51.1% compared with the same period in 2021. The company's operating income and net profit were both significantly higher than those of the same period in 2021.

During the reporting period, the company's operating income was RMB44.3 million, an increase of 51.1% compared with the same period in 2021, and the net profit was RMB6.7 million, an increase of 51.1% compared with the same period in 2021.

The company's operating income and net profit were both significantly higher than those of the same period in 2021. The company's operating income and net profit were both significantly higher than those of the same period in 2021.

	February 28, 2022 (RMB'000)	December 31, 2021 (RMB'000)
Operating income	-15,927	-6,566
Operating profit	18,063	7,075
Operating loss	714	6,429
	2,850	6,938

During the reporting period, the company's operating income was RMB2.9 million, an increase of 51.1% compared with the same period in 2021, and the net profit was RMB-15.9 million, an increase of 51.1% compared with the same period in 2021. The company's operating income and net profit were both significantly higher than those of the same period in 2021.

During the reporting period, the company's operating income was RMB2.9 million, an increase of 51.1% compared with the same period in 2021, and the net profit was RMB-15.9 million, an increase of 51.1% compared with the same period in 2021.

The company's operating income and net profit were both significantly higher than those of the same period in 2021. The company's operating income and net profit were both significantly higher than those of the same period in 2021.

During the reporting period, the company's operating income was RMB2.9 million, an increase of 51.1% compared with the same period in 2021, and the net profit was RMB-15.9 million, an increase of 51.1% compared with the same period in 2021.

The company's operating income and net profit were both significantly higher than those of the same period in 2021. The company's operating income and net profit were both significantly higher than those of the same period in 2021.

Management Discussion and Analysis

Non-Operating Income and Non-Operating Expenses

Other income and other expenses are mainly related to the company's non-core business activities. In 2022, the company's non-operating income was 55 thousand RMB, and non-operating expenses were 7,436 thousand RMB. In 2021, the company's non-operating income was 266 thousand RMB, and non-operating expenses were 9,470 thousand RMB. The company's non-operating income and expenses are not directly related to the company's core business activities.

	For the year ended December 31, 2022 (in MB'000)	2021 (RMB'000)
Government grants	55	266
Other income	7,436	9,470
Other expenses		1,800
Other income	1,063	300
Non-operating income	8,554	11,836
Losses on disposal of long-term assets	1,588	166
Other income	3,928	3,333
Other expenses	1,754	1,399
Other income		2,000
Other expenses	2,071	1,739
Non-operating expenses	9,341	8,637

During the reporting period, the company's non-operating income was 8,554 thousand RMB, and non-operating expenses were 9,341 thousand RMB. The company's non-operating income and expenses are not directly related to the company's core business activities. In 2021, the company's non-operating income was 11,836 thousand RMB, and non-operating expenses were 8,637 thousand RMB. The company's non-operating income and expenses are not directly related to the company's core business activities.

Investment Income

During the reporting period, the company's investment income was 26.6 million RMB (2021: 54.8 million RMB), which was 51.5% of the company's total income. In 2021, the company's investment income was 54.8 million RMB, which was 170.3% of the company's total income. In 2022, the company's investment income was 26.6 million RMB, which was 57.3% of the company's total income.

Management Discussion and Analysis

Financial Position

Assets

As of December 31, 2022, the Company's total assets were RMB58.3 million (December 31, 2021: RMB56.5 million), an increase of 3.2%.

Assets

As of December 31, 2022, the Company's total assets were RMB382.8 million (December 31, 2021: RMB311.8 million), an increase of 22.8%. The increase was mainly due to the increase in the balance of the "Prepaid Expenses" account.

During the reporting period, the Company's total assets were RMB42 million (2021: 37 million).

Other Assets and Prepaid Expenses

As of December 31, 2022, the Company's total assets were RMB69.4 million (December 31, 2021: RMB41.8 million).

Other Assets and Prepaid Expenses

As of December 31, 2022, the Company's total assets were RMB63.1 million (December 31, 2021: RMB65.8 million). During the reporting period, the Company's total assets were RMB2.7 million, an increase of 41.5%. The increase was mainly due to the increase in the balance of the "Prepaid Expenses" account.

C

As of December 31, 2022, the Company's total assets were RMB152.5 million (December 31, 2021: RMB43.8 million), an increase of 246.8%. The increase was mainly due to the increase in the balance of the "Prepaid Expenses" account.

R - - A

As of December 31, 2022, the Company's total assets were RMB190.4 million (December 31, 2021: RMB257.4 million), a decrease of 26.0%. The decrease was mainly due to the decrease in the balance of the "Prepaid Expenses" account.

A

As of December 31, 2022, the Company's total assets were RMB85.8 million (December 31, 2021: RMB69.2 million).

Management Discussion and Analysis

Risks Associated with Capital

As of December 31, 2022, the company's total assets were RMB 29.9 million (December 31, 2021: RMB16.3 million).

Operating Performance

As of December 31, 2022, the company's operating income was RMB72.2 million (December 31, 2021 (audited)): RMB57.3 million), and the net profit was RMB17.0 million (December 31, 2021 (audited): RMB10.5 million).

Financial Position and Capital

The company's financial position is stable, and the capital structure is reasonable. The company's financial position is as follows:

	Financial Position as of December 31, 2022 (in MB'000)	Financial Position as of December 31, 2021 (RMB'000)
Net assets	227,221	193,896
Net income		

M 2022 12 31 A

NC 2022 12 31 A

D 2022 12 31 RMB116.2

S 2022 12 31 A D

T 2022 12 31 R P

A 2022 12 31 G B

I 2022 12 31

B B

A D 2022 12 31, 2021: RMB553.2), RMB402.7 R P RMB616.5 (D RMB339.4

M 2022 12 31 A

2022 12 31 2021 12 31

T G 2022 12 31 2021 12 31

A D 31, 2022, G 2021 12 31

G R

A D 31, 2022, G 2021 12 31

E 2022 12 31 R 2021 12 31 P 2022 12 31

A D 31, 2022, G 2021 12 31

S I P

I 2022 12 31 2021 12 31

M 1 D 1 A 1

- (3) D 1 E 1 I 1 S
- (4) F 1 E 1 I 1 S
T C 1 , 1
1 , 1 I 1 S 1
P 1 . W I 1 S 1 P 1 , P 1
1 S 1 C 1 T P 1
1 I 1 S 1 - 1 I 1 S 1
P 1
1 T 1
1 U 1 - 1 , P 1
1 I 1 S 1
P 1 .
- () S 1 S 1 E 1 I 1 S
T I 1 S 1 E 1 I 1 S 1 - 1 - D
S 1 , 1 C 1
- () A 1 E 1 I 1 S 1
1 C 1
P 1 2,460,000 S 1 E 1 I 1 S 1 ,
3.30% C 1 , 1
4.45% - 1 - D 1 S 1 .

M 1 D 1 A 1

- (4) V_{eff} , - $E_{\text{eff}} I_{\text{eff}} S$
- (a) V_{eff} $E_{\text{eff}} I_{\text{eff}} S$
 T_{eff} $E_{\text{eff}} I_{\text{eff}} S$ 10 $E_{\text{eff}} I_{\text{eff}} S$
 2017 (. . A 26, 2018),
 $E_{\text{eff}} I_{\text{eff}} S$.
- () L - $E_{\text{eff}} I_{\text{eff}} S$
 T_{eff} - $I_{\text{eff}} S$ P_{eff} 48 , $E_{\text{eff}} I_{\text{eff}} S$.
- () U $E_{\text{eff}} I_{\text{eff}} S$
 $I_{\text{eff}} S$ $E_{\text{eff}} I_{\text{eff}} S$ 48 (J 28, 2022)
 (J 29, 2018); $I_{\text{eff}} S$ $E_{\text{eff}} I_{\text{eff}} S$.
- (5) G_{eff} $E_{\text{eff}} I_{\text{eff}} S$
- () T_{eff} P_{eff} P_{eff} P_{eff} .
- () $T_{\text{eff}} C_{\text{eff}}$ $D_{\text{eff}} N_{\text{eff}}$ P_{eff} $G_{\text{eff}} D_{\text{eff}}$.
- () T_{eff} P_{eff} $D_{\text{eff}} N_{\text{eff}}$ C_{eff} C_{eff}
- (V) W C_{eff} P_{eff} C_{eff}
 $I_{\text{eff}} S$ (C_{eff}) C_{eff}
- (V) $T_{\text{eff}} C_{\text{eff}}$ $E_{\text{eff}} I_{\text{eff}} S$ S_{eff}
 P_{eff} , P_{eff} , P_{eff} .

M 1 D 1 A 1

- (6) G P E I S S
- (a) G P E I S T G P I S RMB10.47 S ; T G P I S RMB10.47 S .
- () B G P E I S B S , G P RMB10.47 E I S I S

M t D A

F
S
D
31, 2022,
I
S
E
I

Name of the Company	Date of the Report	Balance Sheet as at 31st December 2022							
		Current Assets		Fixed Assets		Current Liabilities		Fixed Liabilities	
		Cost	Net Book Value	Cost	Net Book Value	Cost	Net Book Value	Cost	Net Book Value
		(H.D.)	(D.T.)	(MB)	(MB)	(P.)	(P.)	(P.)	(P.)
D									
M. WANG L ()	J 18, 2021	35.95	J 28, 2022	10.47	248,328	-	248,328	-	-
M. WANG H ()	J 18, 2021	35.95	J 28, 2022	10.47	95,511	-	95,511	-	-
S									
M. SUN F ()	J 18, 2021	35.95	J 28, 2022	10.47	14,327	-	14,327	-	-
M. XIE T	J 18, 2021	35.95	J 28, 2022	10.47	4,776	-	4,776	-	-
O									
M. XU Y (M. WANG H)	J 18, 2021	35.95	J 28, 2022	10.47	28,653	-	28,653	-	-
M. WANG B (M. WANG L)	J 18, 2021	35.95	J 28, 2022	10.47	4,776	-	4,776	-	-
M. WANG H (M. XU Q)	J 18, 2021	35.95	J 28, 2022	10.47	4,776	-	4,776	-	-
M. GUAN W ()	J 18, 2021	35.95	J 28, 2022	10.47	19,102	-	19,102	-	-
M. SUN H (M. WANG L)	J 18, 2021	35.95	J 28, 2022	10.47	30,563	-	30,563	-	-
M. WANG H ()	J 18, 2021	35.95	J 28, 2022	10.47	4,776	-	4,776	-	-
M. ZHANG L ()	J 18, 2021	35.95	J 28, 2022	10.47	4,776	-	4,776	-	-
M. GUAN W ()	J 18, 2021	35.95	J 28, 2022	10.47	4,776	-	4,776	-	-

E T P

T C , -

, T C

- -

Report of the Board

The Board of Directors of Wenzhou Kangning Hospital Co., Ltd. (hereinafter referred to as "the Company") has reviewed the Company's financial statements for the year ended December 31, 2022.

The Board of Directors of the Company has reviewed the Company's financial statements for the year ended December 31, 2022.

The Board of Directors of the Company has reviewed the Company's financial statements for the year ended December 31, 2022. The Board of Directors of the Company has reviewed the Company's financial statements for the year ended December 31, 2022. The Board of Directors of the Company has reviewed the Company's financial statements for the year ended December 31, 2022.

C R L R

T C , ,
PRC C L , H K L R , SFO, H K C O ,
S , , C T C
B D .

L G M
H L PRC 《中華人民共和國精神衛生法》, L P ' R C P
B M H G 《中華人民共和國基本醫療衛生與健康促進法》(J 1, 2020),
M R M I 《醫療機構管理條例》 R I
M R M I 《醫療機構管理條例實施細則》.

T G . I
.

T C . T D
G 2022 L P D .

P I P

F D 31, 2022, G .

U P I P O

Report of the Board

Director's Report

This report summarizes the business performance of Wenzhou Kangning Hospital Co., Ltd. (the "Company") for the period from January 1, 2022, to December 31, 2022.

Business Performance

In accordance with the provisions of the Company Law of the People's Republic of China (《中華人民共和國企業所得稅法》), the Company has implemented the following tax policies and procedures for the period from January 1, 2008, to December 31, 2022:

The Company is a resident enterprise in the People's Republic of China. According to the provisions of the Company Law of the People's Republic of China, the Company is subject to corporate income tax at a rate of 25% on its taxable income. The Company has been approved by the State Taxation Administration as a high-tech enterprise, and its corporate income tax rate is reduced to 15%.

The Company has established a complete system of internal control over financial reporting, and the financial statements are audited by a qualified independent accounting firm. The Company's financial statements are prepared in accordance with the accounting standards and regulations of the People's Republic of China.

In accordance with the provisions of the Company Law of the People's Republic of China, the Company has implemented the following tax policies and procedures for the period from January 1, 2008, to December 31, 2022:

The Company is a resident enterprise in the People's Republic of China. According to the provisions of the Company Law of the People's Republic of China, the Company is subject to corporate income tax at a rate of 25% on its taxable income. The Company has been approved by the State Taxation Administration as a high-tech enterprise, and its corporate income tax rate is reduced to 15%.

The Company has established a complete system of internal control over financial reporting, and the financial statements are audited by a qualified independent accounting firm. The Company's financial statements are prepared in accordance with the accounting standards and regulations of the People's Republic of China.

The Company has implemented the following tax policies and procedures for the period from January 1, 2008, to December 31, 2022:

The Company is a resident enterprise in the People's Republic of China. According to the provisions of the Company Law of the People's Republic of China, the Company is subject to corporate income tax at a rate of 25% on its taxable income. The Company has been approved by the State Taxation Administration as a high-tech enterprise, and its corporate income tax rate is reduced to 15%.

The Company has established a complete system of internal control over financial reporting, and the financial statements are audited by a qualified independent accounting firm. The Company's financial statements are prepared in accordance with the accounting standards and regulations of the People's Republic of China.

Report of the Board

DIRECTORS' REPORT

For the period from January 1, 2022, to December 31, 2022, the Board of Directors has completed its duties in accordance with the provisions of the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the Listing Rules of the Shanghai Stock Exchange, and the Articles of Association of the Company, and has formulated the following resolutions:

1. Review and Approval of the Company's Business Performance

For the period from January 1, 2022, to December 31, 2022, the Board of Directors has reviewed and approved the Company's business performance, and has formulated the following resolutions:

2. Review and Approval of the Company's Financial Performance

For the period from January 1, 2022, to December 31, 2022, the Board of Directors has reviewed and approved the Company's financial performance, and has formulated the following resolutions:

3. Review and Approval of the Company's Human Resources Management

For the period from January 1, 2022, to December 31, 2022, the Board of Directors has reviewed and approved the Company's human resources management, and has formulated the following resolutions:

4. Review and Approval of the Company's Risk Management

For the period from January 1, 2022, to December 31, 2022, the Board of Directors has reviewed and approved the Company's risk management, and has formulated the following resolutions:

5. Review and Approval of the Company's Environmental Management

M. GUAN W (Chairman)

M. WANG L (Vice Chairman)

M. WANG H (Secretary) (Term expires December 31, 2022)

6. Review and Approval of the Company's Social Responsibility Management

M. QIN H

M. LI C

7. Review and Approval of the Company's Information Management

M. ZHONG W

M. LIU N

M. ZHAO X (Term expires March 10, 2023)

S

T S R P :

M . XUN (C) (F ,19, 2022)

M . XU Y

M . XIE T

M . QIAN C

M . SUN F (C) (F ,15, 2022)

M . CHEN J (,17, 2022)

B R A K I F P

F , G D 31, 2022, F H M D A

D ' S ' I T , A C

S R B - C T N F S - R
C ,
D S , D S ,
D 31, 2022 R P .

C S ' I C S

S R B - C T N F S - R
C S
G C

M C

D R P , C
C

Report of the Board

N - A

P / G G N - A D 31, 2022, C S P) C S .

T C A D D 31, 2022. C S N - 31, 2022 S , N - A

D
E

P D 31, 2022 N F S - R C G
 D T C
 R

N D R P .

D ' I C B

D R P , D H K L

$$\begin{array}{ccccccc}
& & & & & & A \dots t \\
& & & & & & A \dots t \quad p \dots t \quad f \\
& & & & & & p \dots t \quad h \quad C \quad y' \\
& & & & & & h \dots f \quad h \quad t \quad I, \\
& & & & & & \\
N \dots & & C \dots f \quad h \dots & N \quad t \dots f \quad I \quad t \dots t & & N \dots f \quad h \dots & f \quad h \dots C \quad (1) \quad h \quad C \quad t \quad (1)
\end{array}$$

Report of the Board

I. Shareholders

As of December 31, 2022, the Company has 336 shareholders, including 100 natural persons, 100 legal persons, and 136 SFOs. The Company has no significant changes in its shareholding structure during the reporting period. The Company's shares are listed on the Shanghai Stock Exchange, and the Company's shares are traded on the Shanghai Stock Exchange. The Company's shares are listed on the Shanghai Stock Exchange, and the Company's shares are traded on the Shanghai Stock Exchange.

Shareholder Name		Number of Shares	Percentage of Total Shares	Percentage of Total Shares
Shareholder Name		Number of Shares	Percentage of Total Shares	Percentage of Total Shares
C E R I D S B		7,466,666(L)	13.51%	10.00%
I F C., L. (Central Enterprise Village Industry Investment Fund Co., Ltd.)				
(C E F)				
S J E M D S I		4,540,000(L)	8.22%	6.09%
C (L P) (Shanghai Jinzhi Enterprise Management Center (Limited Partnership)) ⁽²⁾				
FAN Y ⁽²⁾	D S I	4,540,000(L)	8.22%	6.09%
SUN J ⁽²⁾	D S I	4,540,000(L)	8.22%	6.09%
S J J E D S I		4,540,000(L)	8.22%	6.09%
I M C., L. (Shanghai Jinpu Jiefu Equity Investment Management Co., Ltd.) ⁽²⁾				
W J E I D S B		4,540,000(L)	8.22%	6.09%
P (L P) (Wenzhou Jinling Equity Investment Co., Ltd. (Limited Partnership)) (J I)				
XU Y ⁽⁶⁾	D S I	5,785,350(L)	10.47%	7.76%
S T I L.P. (Shanghai Haizhi Ying Investment Co., Ltd. (Limited Partnership))	D S B	4,519,003(L)	8.18%	6.06%

A									
P									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									
N									
C									

Report of the Board

N :

(L): L

- (1) T 55,260,000 D S 19,340,300 H S (74,600,300 S) C D 31, 2022.
- (2) FAN Y 50% S J E M C (L P) (上海金浙企業管理中心(有限合夥)) S J E M C (L P) (上海金浙企業管理中心(有限合夥)) W J E I P (L P) (溫州金寧股權投資合夥企業(有限合夥)). SUN J 33.94% W J E I P (L P) (溫州金寧股權投資合夥企業(有限合夥)). S J J E I M C , L . (上海金浦健服股權投資管理有限公司) W J E I P (L P) . T , XV SFO, FAN Y , S J E M C (L P) (上海金浙企業管理中心(有限合夥)), SUN J S J J E I M C , L . (上海金浦健服股權投資管理有限公司) D S W J E I P (L P) (溫州金寧股權投資合夥企業(有限合夥)) C
- (3) S L I L.P. (上海樂進投資合夥企業(有限合夥)) 99.99% S T I L.P. (上海檀英投資合夥企業(有限合夥)). T , XV SFO, S L I L.P. (上海樂進投資合夥企業(有限合夥)) D S S T I L.P. (上海檀英投資合夥企業(有限合夥)) C
- (4) S L V I M C , L (上海正心谷投資管理有限公司) (S S I M C , L (上海盛歌投資管理有限公司)) S Q I M P (L.P.) (上海乾剛投資管理合夥企業(有限合夥)) S T I L.P. (上海檀英投資合夥企業(有限合夥)). T , XV SFO, S L V I M C , L D S S Q I M P (L.P.) (上海乾剛投資管理合夥企業(有限合夥)) (1,987,356 D S C S T I L.P. (上海檀英投資合夥企業(有限合夥)) C
- (5) Q J H I C , L . (青島金石灝汭投資有限公司) J I C , L . (金石投資有限公司). T , J I C , L . (金石投資有限公司) D S Q J H I I C , L . (青島金石灝汭投資有限公司) C J XV SFO.
- (6) M . WANG H N X K I M L.P. N E K I M P (L P) 50.62% 37.10%, , XV SFO, M . WANG H D S M . XU Y M . WANG H . M . XU Y D S M . WANG H XV SFO.

S , D 31, 2022, D , (D , S C , D 2 3 P XV SFO, C S 336 SFO.



Report of the Board

C G

So, $\mathcal{R} \subseteq \mathcal{P}$, $\mathcal{C} \subseteq \mathcal{P}$, $\mathcal{C} \subseteq \mathcal{R}$, $\mathcal{C} \subseteq \mathcal{C} \subseteq \mathcal{P}$, $\mathcal{C} \subseteq \mathcal{C} \subseteq \mathcal{P}$, $\mathcal{C} \subseteq \mathcal{C} \subseteq \mathcal{P}$, $\mathcal{C} \subseteq \mathcal{C} \subseteq \mathcal{P}$.

F M 10, 2023, M . ZHAO X (M . Z) B , C . F M . Z , H K L R : () B R 3.10 H K L R ; () R 3.25 H K L R ; () R 3.27A H K L R . O M 10, 2023, B M . JIN L (M . J) D , C T C M . J D .

S P F

B_a
P_a, D_a, C_a, S_a, L_a, H_a

I B R P

T R P N XIII F S - B

A C

T A C B D C C G ' 2022
S B E . 2022 C A

A

T (BDO), BDO C, S, L, P, C, P, A, LLP

Report of the Board

(2) C 2020

(Unit: RMB,)

Item	Amount	Change	Balance
Operating income	63,465,824	-12,878	63,478,702
Operating expenses	542,683,617	-12,878	542,696,495
Operating profit	2,161,261,775	-12,878	2,161,274,653
Operating profit	76,603,400	-9,203,741	85,807,141
Operating profit	606,077,103	-9,203,741	615,280,844
Operating profit	946,349,216	-9,203,741	955,552,957
Operating profit	214,856,099	9,190,863	205,665,236
Operating profit	1,122,247,550	9,190,863	1,113,056,686
Operating profit	1,214,912,559	9,190,863	1,205,721,695
Operating profit	2,161,261,775	-12,878	2,161,274,653

(3) C 2021

(Unit: RMB,)

Item	Amount	Change	Balance
Operating income	29,925,488	-12,878	29,938,366
Operating expenses	609,602,623	-12,878	609,615,501
Operating profit	2,377,954,989	-12,878	2,377,967,867
Operating profit	57,319,524	-9,203,741	66,523,265
Operating profit	535,774,635	-9,203,741	544,978,376
Operating profit	1,097,675,868	-9,203,741	1,106,879,609
Operating profit	6,937,845	-12,878	6,950,723
Operating profit	257,098,624	9,190,863	247,907,761
Operating profit	1,208,263,897	9,190,863	1,199,073,034
Operating profit	1,280,279,120	9,190,863	1,271,088,257
Operating profit	2,377,954,989	-12,878	2,377,967,867

Opinions of the Independent Non-executive Directors

T
- 56
C
A
S
B
E
C
T
T
T

Opinions of the Board

T B
C
C
T B
A
A
C
A
T B

Opinions of the Supervisory Committee

T S
C
C
T S
C

Opinions of the Audit Committee

T A C
S B E
C
T A C
N XV F S - O

C S T

F ♀ ♀ B ♀
GUAN W
C ♀ ♀

Z  , PRC
A 14, 2023

T S :

I 2022, S C , PRC C L , A ,
S C , B , S
C ,
D C S .

D R P , S C B C
C C

T S C - C R
P , D B ,

I 2023, S C -
. T , S C
, S C

F S C
XUN
C

Z , PRC
A 14, 2023

Corporate Governance Report

本公司严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股权激励管理办法》等法律法规和规范性文件的要求，不断完善公司治理结构，确保股东能够充分行使权利，董事会、监事会和独立董事能够独立、客观、公正地履行职责，切实保障中小投资者的利益。

一、基本情况

（一）公司治理结构

本公司严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股权激励管理办法》等法律法规和规范性文件的要求，不断完善公司治理结构，确保股东能够充分行使权利，董事会、监事会和独立董事能够独立、客观、公正地履行职责，切实保障中小投资者的利益。

本公司严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股权激励管理办法》等法律法规和规范性文件的要求，不断完善公司治理结构，确保股东能够充分行使权利，董事会、监事会和独立董事能够独立、客观、公正地履行职责，切实保障中小投资者的利益。

本公司严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股权激励管理办法》等法律法规和规范性文件的要求，不断完善公司治理结构，确保股东能够充分行使权利，董事会、监事会和独立董事能够独立、客观、公正地履行职责，切实保障中小投资者的利益。

本公司严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股权激励管理办法》等法律法规和规范性文件的要求，不断完善公司治理结构，确保股东能够充分行使权利，董事会、监事会和独立董事能够独立、客观、公正地履行职责，切实保障中小投资者的利益。

本公司严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股权激励管理办法》等法律法规和规范性文件的要求，不断完善公司治理结构，确保股东能够充分行使权利，董事会、监事会和独立董事能够独立、客观、公正地履行职责，切实保障中小投资者的利益。

Corporate Governance Report

REPORT OF THE BOARD OF DIRECTORS

The Board of Directors has reviewed the Company's financial statements and the related audit report issued by the independent accounting firm. The Board of Directors has confirmed that the financial statements are true and accurate, and the audit report is reasonable. The Board of Directors has also reviewed the Company's business performance and the related information disclosed in the annual report. The Board of Directors has confirmed that the Company's business performance is in line with the Company's business plan and the related information disclosed in the annual report is true and accurate.

The Board of Directors has also reviewed the Company's internal control system and the related information disclosed in the annual report. The Board of Directors has confirmed that the Company's internal control system is effective and the related information disclosed in the annual report is true and accurate. The Board of Directors has also reviewed the Company's risk management system and the related information disclosed in the annual report. The Board of Directors has confirmed that the Company's risk management system is effective and the related information disclosed in the annual report is true and accurate.

In addition, the Board of Directors has also reviewed the Company's environmental, social and governance (ESG) performance and the related information disclosed in the annual report. The Board of Directors has confirmed that the Company's ESG performance is in line with the Company's ESG policy and the related information disclosed in the annual report is true and accurate.

The Board of Directors has also reviewed the Company's corporate governance structure and the related information disclosed in the annual report. The Board of Directors has confirmed that the Company's corporate governance structure is in line with the Company's corporate governance policy and the related information disclosed in the annual report is true and accurate.

The Board of Directors has also reviewed the Company's human resources management and the related information disclosed in the annual report. The Board of Directors has confirmed that the Company's human resources management is in line with the Company's human resources management policy and the related information disclosed in the annual report is true and accurate.

REPORT OF THE SUPERVISORS

Corporate Governance Report

C	D	S	C	E
O D 31, 2021, C M . JIN H			, M . WANG H	J 10, 2022.
O J 17, 2022, S			, M . CHEN J	
O F 15, 2022, S			S	
O F 19, 2022, S			C M . XU N	
O J 12, 2022, M . NG W			C (C	
4T) C H KH 4T T 0 16 C DO 622 C I D KH				

On July 5, 2023, C. M. WANG L. (M.), D., M. W. 100,000 S C M. W. J., C RMB13.28 S D 19, 2022 (D.). P D, M. W. / B D C A M. W. S C B - P C C D C, C M. W. A.3 B.8 M C.

Corporate Governance Report

本公司严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股权激励管理办法》等法律法规和规范性文件的要求，不断完善公司治理，建立健全各项内部控制制度，加强信息披露工作，切实维护公司全体股东和债权人的合法权益。

- (1) 报告期内，公司严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股权激励管理办法》等法律法规和规范性文件的要求，不断完善公司治理，建立健全各项内部控制制度，加强信息披露工作，切实维护公司全体股东和债权人的合法权益。
- (2) 报告期内，公司严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股权激励管理办法》等法律法规和规范性文件的要求，不断完善公司治理，建立健全各项内部控制制度，加强信息披露工作，切实维护公司全体股东和债权人的合法权益。
- (3) 报告期内，公司严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股权激励管理办法》等法律法规和规范性文件的要求，不断完善公司治理，建立健全各项内部控制制度，加强信息披露工作，切实维护公司全体股东和债权人的合法权益。

报告期内，公司严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股权激励管理办法》等法律法规和规范性文件的要求，不断完善公司治理，建立健全各项内部控制制度，加强信息披露工作，切实维护公司全体股东和债权人的合法权益。

报告期内，公司严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股权激励管理办法》等法律法规和规范性文件的要求，不断完善公司治理，建立健全各项内部控制制度，加强信息披露工作，切实维护公司全体股东和债权人的合法权益。

报告期内，公司严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股权激励管理办法》等法律法规和规范性文件的要求，不断完善公司治理，建立健全各项内部控制制度，加强信息披露工作，切实维护公司全体股东和债权人的合法权益。

Corporate Governance Report

C

O Ma 10, 2023, , M . ZHAO X , B . F , M . ZHAO X , H K L R 3.10 R 3.25 H K L R ; () R 3.27A H K L R . O Ma 10, 2023, B C M . JIN L D B . A C M . JIN L Ma 10, 2023.

S , B CG C R P .

S C D S

E D (- D) S

T D S A , C

A S

T C C A S B E 2017, C O (C 622 H K) (C O) .

A P

A , t P

T A S B E - B S , M F F 15, 2006 (A , t t f B E t) .

T . T H K C O H K C O .

Corporate Governance Report

一、公司治理

本公司严格按照《公司法》《证券法》《上市公司治理准则》《上海证券交易所科创板股票上市规则》《上市公司信息披露管理办法》《上市公司股权激励管理办法》等法律法规和规范性文件的要求，不断完善公司治理结构，确保股东能够充分行使权利，董事会、监事会和独立董事能够独立、客观、公正地履行职责，切实保障社会公众股东的合法权益。

二、公司治理的实际情况

本公司严格按照《公司法》《证券法》《上市公司治理准则》《上海证券交易所科创板股票上市规则》《上市公司信息披露管理办法》《上市公司股权激励管理办法》等法律法规和规范性文件的要求，不断完善公司治理结构，确保股东能够充分行使权利，董事会、监事会和独立董事能够独立、客观、公正地履行职责，切实保障社会公众股东的合法权益。

本公司严格按照《公司法》《证券法》《上市公司治理准则》《上海证券交易所科创板股票上市规则》《上市公司信息披露管理办法》《上市公司股权激励管理办法》等法律法规和规范性文件的要求，不断完善公司治理结构，确保股东能够充分行使权利，董事会、监事会和独立董事能够独立、客观、公正地履行职责，切实保障社会公众股东的合法权益。

本公司严格按照《公司法》《证券法》《上市公司治理准则》《上海证券交易所科创板股票上市规则》《上市公司信息披露管理办法》《上市公司股权激励管理办法》等法律法规和规范性文件的要求，不断完善公司治理结构，确保股东能够充分行使权利，董事会、监事会和独立董事能够独立、客观、公正地履行职责，切实保障社会公众股东的合法权益。

三、公司治理的改进情况

本公司严格按照《公司法》《证券法》《上市公司治理准则》《上海证券交易所科创板股票上市规则》《上市公司信息披露管理办法》《上市公司股权激励管理办法》等法律法规和规范性文件的要求，不断完善公司治理结构，确保股东能够充分行使权利，董事会、监事会和独立董事能够独立、客观、公正地履行职责，切实保障社会公众股东的合法权益。

四、公司治理的未来规划

本公司严格按照《公司法》《证券法》《上市公司治理准则》《上海证券交易所科创板股票上市规则》《上市公司信息披露管理办法》《上市公司股权激励管理办法》等法律法规和规范性文件的要求，不断完善公司治理结构，确保股东能够充分行使权利，董事会、监事会和独立董事能够独立、客观、公正地履行职责，切实保障社会公众股东的合法权益。

五、公司治理的自我评价

本公司严格按照《公司法》《证券法》《上市公司治理准则》《上海证券交易所科创板股票上市规则》《上市公司信息披露管理办法》《上市公司股权激励管理办法》等法律法规和规范性文件的要求，不断完善公司治理结构，确保股东能够充分行使权利，董事会、监事会和独立董事能够独立、客观、公正地履行职责，切实保障社会公众股东的合法权益。

本公司严格按照《公司法》《证券法》《上市公司治理准则》《上海证券交易所科创板股票上市规则》《上市公司信息披露管理办法》《上市公司股权激励管理办法》等法律法规和规范性文件的要求，不断完善公司治理结构，确保股东能够充分行使权利，董事会、监事会和独立董事能够独立、客观、公正地履行职责，切实保障社会公众股东的合法权益。

本公司严格按照《公司法》《证券法》《上市公司治理准则》《上海证券交易所科创板股票上市规则》《上市公司信息披露管理办法》《上市公司股权激励管理办法》等法律法规和规范性文件的要求，不断完善公司治理结构，确保股东能够充分行使权利，董事会、监事会和独立董事能够独立、客观、公正地履行职责，切实保障社会公众股东的合法权益。

Corporate Governance Report

Director, Chairman of the Board	Director
Independent Director	Non-independent Director
Number of Shares Held / Total Shares	
Executive Director	
M. GUAN W (Chairman)	1/1
M. WANG L	1/1
M. WANG H (S 1, 2022)	0/0
Non-executive Director	
M. QIN H	1/1
M. LI C	1/1
Independent Non-executive Director	
M. ZHAO X (M 10, 2023)	1/1
M. ZHONG W	1/1
M. LIU N	1/1

Corporate Governance Report

B 董事

本公司董事会由5名董事组成，其中独立董事3名，非独立董事2名。董事会下设战略委员会、薪酬与考核委员会、提名委员会、审计委员会、关联交易控制委员会、风险管理委员会、环境、社会及治理委员会等7个专门委员会。董事会秘书为陈伟，负责公司信息披露、投资者关系管理、证券事务等工作。董事会办公室设在人力资源部，负责公司日常行政、人事、财务、法律、合规、风控等工作。

A 高级管理人员

本公司高级管理人员包括总经理、副总经理、财务总监、董事会秘书、总工程师、总会计师、总法律顾问等。高级管理人员的聘任和解聘由董事会决定。高级管理人员的薪酬由薪酬与考核委员会拟定，经董事会审议通过后实施。高级管理人员的考核由董事会决定。高级管理人员的任免程序如下：高级管理人员的提名由董事会提名委员会负责，经董事会审议通过后，由董事会聘任。高级管理人员的解聘由董事会决定。高级管理人员的薪酬由薪酬与考核委员会拟定，经董事会审议通过后实施。高级管理人员的考核由董事会决定。高级管理人员的任免程序如下：高级管理人员的提名由董事会提名委员会负责，经董事会审议通过后，由董事会聘任。高级管理人员的解聘由董事会决定。高级管理人员的薪酬由薪酬与考核委员会拟定，经董事会审议通过后实施。高级管理人员的考核由董事会决定。

本公司高级管理人员的聘任和解聘由董事会决定。高级管理人员的薪酬由薪酬与考核委员会拟定，经董事会审议通过后实施。高级管理人员的考核由董事会决定。高级管理人员的任免程序如下：高级管理人员的提名由董事会提名委员会负责，经董事会审议通过后，由董事会聘任。高级管理人员的解聘由董事会决定。高级管理人员的薪酬由薪酬与考核委员会拟定，经董事会审议通过后实施。高级管理人员的考核由董事会决定。

本公司高级管理人员的聘任和解聘由董事会决定。高级管理人员的薪酬由薪酬与考核委员会拟定，经董事会审议通过后实施。高级管理人员的考核由董事会决定。高级管理人员的任免程序如下：高级管理人员的提名由董事会提名委员会负责，经董事会审议通过后，由董事会聘任。高级管理人员的解聘由董事会决定。高级管理人员的薪酬由薪酬与考核委员会拟定，经董事会审议通过后实施。高级管理人员的考核由董事会决定。

本公司高级管理人员的聘任和解聘由董事会决定。高级管理人员的薪酬由薪酬与考核委员会拟定，经董事会审议通过后实施。高级管理人员的考核由董事会决定。高级管理人员的任免程序如下：高级管理人员的提名由董事会提名委员会负责，经董事会审议通过后，由董事会聘任。高级管理人员的解聘由董事会决定。高级管理人员的薪酬由薪酬与考核委员会拟定，经董事会审议通过后实施。高级管理人员的考核由董事会决定。

姓名	职务	任期
M. ZHONG W (C 董事)	董事	5/5
M. LIU N	董事	5/5
M. LI C	董事	5/5

Corporate Governance Report

一、公司治理

本公司严格按照《公司法》《证券法》《上市公司治理准则》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第1号——主板上市公司规范运作》《深圳证券交易所创业板上市公司规范运作指引》等法律法规和规范性文件的要求，不断完善公司治理，建立健全各项内部控制制度，加强信息披露管理，进一步规范公司运作，提高公司治理水平。

报告期内，公司严格按照《公司法》《证券法》《上市公司治理准则》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第1号——主板上市公司规范运作》《深圳证券交易所创业板上市公司规范运作指引》等法律法规和规范性文件的要求，不断完善公司治理，建立健全各项内部控制制度，加强信息披露管理，进一步规范公司运作，提高公司治理水平。

报告期内，公司严格按照《公司法》《证券法》《上市公司治理准则》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第1号——主板上市公司规范运作》《深圳证券交易所创业板上市公司规范运作指引》等法律法规和规范性文件的要求，不断完善公司治理，建立健全各项内部控制制度，加强信息披露管理，进一步规范公司运作，提高公司治理水平。

报告期内，公司严格按照《公司法》《证券法》《上市公司治理准则》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第1号——主板上市公司规范运作》《深圳证券交易所创业板上市公司规范运作指引》等法律法规和规范性文件的要求，不断完善公司治理，建立健全各项内部控制制度，加强信息披露管理，进一步规范公司运作，提高公司治理水平。

报告期内，公司严格按照《公司法》《证券法》《上市公司治理准则》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第1号——主板上市公司规范运作》《深圳证券交易所创业板上市公司规范运作指引》等法律法规和规范性文件的要求，不断完善公司治理，建立健全各项内部控制制度，加强信息披露管理，进一步规范公司运作，提高公司治理水平。

姓名	职务	任期起止日期
M. LIU N	(C)	2/2
M. GUAN W		2/2
M. ZHAO X	(M 10, 2023)	2/2

报告期内，公司严格按照《公司法》《证券法》《上市公司治理准则》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第1号——主板上市公司规范运作》《深圳证券交易所创业板上市公司规范运作指引》等法律法规和规范性文件的要求，不断完善公司治理，建立健全各项内部控制制度，加强信息披露管理，进一步规范公司运作，提高公司治理水平。

Corporate Governance Report

R C

T C R C R C B . T CG C
R C D
D
D
;
,
C 17 H K L R ;
C
B .

A, R C - D, M. ZHONG W M. LIU N. T R C E.1.2() CG C (. . B D). O R C R P, C 2021.

T D R C R P

N **f**
t

D. . . . t . . .

/ tt

M. ZHAO X (C. J.) (M. 10, 2023)

1/1

M. ZHONG W

1/1

M. LIU N

1/1

T  G  D  C  . T  -  D  ,  B  .

T D 31, 2022 N F S -

Corporate Governance Report

S  R  C
T C   S  R  C

Corporate Governance Report

董事、监事及高级管理人员基本情况

年龄	性别	学历	专业职称	是否取得独立董事任职资格
30-49 (3)	男 (33.3%)	1-5 (4)		
50-59 (3)	男 (66.7%)	6-10 (2)		

截至2022年12月31日，公司共有董事4名，其中独立董事2名，非独立董事2名。董事中，本科学历3名，大专学历1名。截至2022年12月31日，公司共有监事2名，其中非独立董事1名，独立董事1名。监事中，本科学历1名，大专学历1名。截至2022年12月31日，公司共有高级管理人员3名，其中本科学历3名。截至2022年12月31日，公司共有核心技术人员2名，其中本科学历2名。

公司治理与内部控制

截至2022年12月31日，公司共有员工4,196名，其中本科及以上学历33.37%，大专及以下学历66.63%。截至2022年12月31日，公司共有研发人员1,000名，其中本科及以上学历66.63%，大专及以下学历33.37%。截至2022年12月31日，公司共有销售人员1,000名，其中本科及以上学历66.63%，大专及以下学历33.37%。截至2022年12月31日，公司共有生产人员1,000名，其中本科及以上学历66.63%，大专及以下学历33.37%。截至2022年12月31日，公司共有财务人员1,000名，其中本科及以上学历66.63%，大专及以下学历33.37%。截至2022年12月31日，公司共有其他人员1,000名，其中本科及以上学历66.63%，大专及以下学历33.37%。

公司治理与内部控制

截至2022年12月31日，公司共有董事4名，其中独立董事2名，非独立董事2名。截至2022年12月31日，公司共有监事2名，其中非独立董事1名，独立董事1名。截至2022年12月31日，公司共有高级管理人员3名，其中本科学历3名。截至2022年12月31日，公司共有核心技术人员2名，其中本科学历2名。

截至2022年12月31日，公司共有研发人员1,000名，其中本科及以上学历66.63%，大专及以下学历33.37%。截至2022年12月31日，公司共有销售人员1,000名，其中本科及以上学历66.63%，大专及以下学历33.37%。截至2022年12月31日，公司共有生产人员1,000名，其中本科及以上学历66.63%，大专及以下学历33.37%。截至2022年12月31日，公司共有财务人员1,000名，其中本科及以上学历66.63%，大专及以下学历33.37%。截至2022年12月31日，公司共有其他人员1,000名，其中本科及以上学历66.63%，大专及以下学历33.37%。

T C . A . T . T . W G . A .



WENZHOU KANGNING HOSPITAL CO., LTD.
2022 ANNUAL REPORT

O J 12, 2022, M . NG W S , SWCS C S G (H K) L , M . WONG W

Corporate Governance Report

C O R P O R A T E G O V E R N A N C E

2022年，公司严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股东大会规则》等法律法规和规范性文件的要求，不断完善公司治理结构，提高公司治理水平，促进公司规范运作。

2022年，公司严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股东大会规则》等法律法规和规范性文件的要求，不断完善公司治理结构，提高公司治理水平，促进公司规范运作。

2022年，公司严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股东大会规则》等法律法规和规范性文件的要求，不断完善公司治理结构，提高公司治理水平，促进公司规范运作。

2022年，公司严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股东大会规则》等法律法规和规范性文件的要求，不断完善公司治理结构，提高公司治理水平，促进公司规范运作。

2022年，公司严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股东大会规则》等法律法规和规范性文件的要求，不断完善公司治理结构，提高公司治理水平，促进公司规范运作。

S E C U R I T Y

2022年，公司严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股东大会规则》等法律法规和规范性文件的要求，不断完善公司治理结构，提高公司治理水平，促进公司规范运作。

2022年，公司严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股东大会规则》等法律法规和规范性文件的要求，不断完善公司治理结构，提高公司治理水平，促进公司规范运作。

2022年，公司严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股东大会规则》等法律法规和规范性文件的要求，不断完善公司治理结构，提高公司治理水平，促进公司规范运作。

2022年，公司严格按照《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《上市公司章程指引》、《上市公司信息披露管理办法》、《上市公司股东大会规则》等法律法规和规范性文件的要求，不断完善公司治理结构，提高公司治理水平，促进公司规范运作。

S B C

Corporate Governance Report

C 董 C 董 D

D R P , A .

D P

T C 10% C C 50% C S C , A C , S A . S C N S

T C ():

(I) ;

(II) ;

(III) , , , , .

T C RMB S . S C S RMB HKD. S HKD S .

T B C

M. G. AN (管偉立), 53, B. D. H. C. H. C. F. 1996

Directors, Supervisors and Senior Management

Non-Executive Directors

M. QIN H (秦浩), 32, Male, Bachelor's Degree, G J 2021. H (上海正心谷投资管理有限公司), S L V I M C., L J 2017 D 2021.

M. Q (秦浩), P U J 2014 H F U J 2017

M. LI Ch h (李昌浩), 33, Male, Bachelor's Degree, G O 2021. H SDIC C I F M C., L . (國投創益產業基金管理有限公司) J 2022, SDIC C I F M C., L . M 2014 D 2021. H Y A C., L . (雲南鋁業股份有限公司), S S

M. (許寧), 49, S. C. H. M. X. C. Ma 2016, C. H. Ma 2016
O 2016, M. X. F. N 2016 D
2017, H. J 2022. H. J 2022. H. C. W TV S (溫州電視台)
M 2023. P. W N
(《溫州新聞聯播》), S 1998 F 2016,

Directors, Supervisors and Senior Management

M. X. B. B. I. (北京廣播學院) C. U.
C. (中國傳媒大學)) J. 1998, H.
(一級人力資源管理師) M. H. R. S. S. P.
R. C. F. 2018.

M. 馮 (徐永久), 45, S . H C O 2021, S A 2023, S J J E I M C ., L . (上海金浦健服股權投資管理有限公司) W J E I P (L P) (溫州金寧股權投資合夥企業(有限合夥)). S J 19, 2018, C Y H C ., L . (成都怡寧醫院有限公司). S F 2016, S Y I C ., L . (上海銀驄投資有限公司). F J 2004 D 2007, D R H S I G . F D 2007 M 2009, I B H A P C . F M 2009 S 2011, S I G S I H S T . F O 2011 O 2015, M . X GP G C ., L . (金浦產業投資基金管理有限公司). F A 2016 M 2023, S J J E I M C ., L . (上海金浦健服股權投資管理有限公司)

M. X. S. U. F. E. J.
2000. H. F. U. ,
S. L. S. F. U. J. 2004. S. J. 2015,
. H. C. E. I. B. S. EMBA (E. M. B.
A.) N. 2022.

M. QIAN (錢成良), 72, S. H. M. Q. C. J. 2017. P. C. Ma, 2007. Ma, 2012, S. S. U. 8.15

S Ma

M. ZHO (周朝毅), 60, . H
C M. Z C F 2005
. H S 2014
C P C N 1995
D 2004, M. Z W G H (温州心血管醫院)
W, . F Ma, 1990 O 1995, M. Z
(

Directors, Supervisors and Senior Management

M. 徐 (徐誼), 48, . H . C M . X C O 2002 (科長) O 2002 Mar 2009, . F A 2009 S 2014, C H P S 2014 C P

M 5B12190CFB0D8

Directors, Supervisors and Senior Management

M 3 IN H (金輝), 36, . H . P C
H C 2022 Z H C P A C
L (浙江華明會計師事務所有限公司) F 2012 D 2021, C
W ; H - ; W
M P ' C N 2018, P
Z H C P A C L ,
W L C P A C L (溫州立德會計師事務所有限公司)

Directors, Supervisors and Senior Management

Director / Supervisor	Director / Supervisor	Director / Supervisor	Director / Supervisor
Mr. Wang L.	Mr. Yang K.	Mr. Hu H.	Mr. Fan J.
	Mr. Chen C., Ltd.	Mr. Ma M.	2017
	Mr. Qian K.	Mr. Hu H.	2018
	Mr. Chen C., Ltd.		
	Mr. Bai Y.	Mr. Hu H.	2019
	Mr. Chen C., Ltd.		
	Mr. Hu H.	Mr. N. N.	2020
	Mr. S. S.	Mr. G. G.	
	Mr. Z. Z.	Mr. F. F.	2022
	Mr. N. N.	Mr. T. T.	
	Mr. Chen C., Ltd.		
	Mr. Z. Z.	Mr. Y. Y.	2022
	Mr. T. T.	Mr. Chen C., Ltd.	
	Mr. Z. Z.	Mr. D. D.	2022
	Mr. P. P.	Mr. Chen C., Ltd.	
	Mr. C. C.	Mr. K. K.	2022
	Mr. H. H.		
	Mr. H. H.	Mr. Chen C., Ltd.	

Directors, Supervisors and Senior Management

Director / Supervisor / Senior Management	Personal Information	Personal Information	Personal Information
M	M	M	Off
XU Y	Q K H S	F A 2011	
	C., L.		
	Y K H S	F S 2013	
	C., L.		
	S Y H S	F S 2014	
	C., L.		
	W Y G S	F N 2015	
	H C., L.		
	B Y H S	F A 2015	
	C., L.		
	S Y M S	F S 2015	
	I C., L.		
	Q Y H S	F N 2015	
	C., L.	N 2022	
	Z H H C	F A 2016	
	M C., L.		
	T K H E	F J 2016	
	C., L.		
	Z K H E	F J 2016	
	M (G) G		
	C., L.		
	H Y H C	F A 2017 A 2022	
	C., L.		
	T L C E	F D 2016	
	H C., L.	M	
	H K H C	F J 2018	
	C., L.		
	H C H E	F N 2017	
	C., L.	G	
	W T TCM E	F J 2018	
	C C., L.		
	W T TCM G	F J 2018	
	C C., L.	A 2022	
	Z J H E	F D 2018	
	T C., L.	G	
	W L Y D	F A 2020	
	H C., L.		
	W J J E	F D 2021	
	T C., L.	G	
	W Y H D	F A 2022	
	T C., L.		

Directors, Supervisors and Senior Management

Director / President Pao-tsun Hsiao
Mr. Hsiao Mr. Hsiao

Directors, Supervisors and Senior Management

Director / Supervisor	Personal Information	Personal Information	Personal Information
M	M	M	Off
ZHANG F	L K H C., L.	E V, Ma	F J 2018
	W N P S H C., L.	D	F J 2019
	L C H C., L.	E V, Ma	F D 2020
YE M	W Y H T C., L.	E V, G	F Ma 2019 J 2022
JIN W	Q Y H C., L.	D	F N 2015 N 2022
	H Y P H C., L.	D	F D 2018
	P C Y H C., L.	E V	F S 2021
	G Y N C C., L.	E V, G	F Ma 2021 D 2022
XUN	G Y H C., L.	E V	F J 2019
	H Y P H C., L.	C	F Ma 2020
JIN H	W O Y E H C., L.	S	F S 2022
	G Y N C C., L.	S	F S 2022

A t ,

X K S B Z [2023] N .ZA12856

h h h f h , H t C ., Lt .,

I. O

[illegible]

I
E (CAS).

II. Background

W $\rightarrow$ C S A (CSA). O
A ' R A F S

III. K_A Ma

K , , . T

Answer

Answer	Hint
1. D The correct answer is D. The correct answer is D.	Hint: The correct answer is D. The correct answer is D.



A t ' t

A. Introduction

IV. Overview

Microsoft (Microsoft) is a company that provides software and services. In 2022, Microsoft reported a revenue of \$211.9 billion. Microsoft is a public company listed on the New York Stock Exchange (NYSE) under the ticker symbol MSFT. Microsoft's headquarters are located in Redmond, Washington, United States.

Microsoft is a company that provides software and services. In 2022, Microsoft reported a revenue of \$211.9 billion. Microsoft is a public company listed on the New York Stock Exchange (NYSE) under the ticker symbol MSFT. Microsoft's headquarters are located in Redmond, Washington, United States.

Microsoft is a company that provides software and services. In 2022, Microsoft reported a revenue of \$211.9 billion. Microsoft is a public company listed on the New York Stock Exchange (NYSE) under the ticker symbol MSFT. Microsoft's headquarters are located in Redmond, Washington, United States.

Microsoft is a company that provides software and services. In 2022, Microsoft reported a revenue of \$211.9 billion. Microsoft is a public company listed on the New York Stock Exchange (NYSE) under the ticker symbol MSFT. Microsoft's headquarters are located in Redmond, Washington, United States.

V. Research Methodology

The research methodology used in this study is a combination of qualitative and quantitative methods. The qualitative methods include interviews with Microsoft executives and analysis of Microsoft's financial statements. The quantitative methods include regression analysis and correlation analysis.

The research methodology used in this study is a combination of qualitative and quantitative methods. The qualitative methods include interviews with Microsoft executives and analysis of Microsoft's financial statements. The quantitative methods include regression analysis and correlation analysis.

The research methodology used in this study is a combination of qualitative and quantitative methods. The qualitative methods include interviews with Microsoft executives and analysis of Microsoft's financial statements. The quantitative methods include regression analysis and correlation analysis.

A. t_0

VI. A

C **t** **B** **h** **t** A 31 D 2022

A E	N V	D 31, 2022	D 31, 2021 (R)	J 31, 2021 (R)
C				
G	(I)	271,094,962.97	188,734,845.77	206,499,564.42
S				
P				
F	(II)	10,641,026.00	10,000,000.00	
D				
N				
A	(III)	382,836,690.89	311,757,875.46	225,300,247.01
R				
A	(VI)	32,201,223.97	11,858,427.06	9,909,510.16
P				
R				
P				
O	(V)	37,195,219.68	29,925,487.99	63,465,823.77
F				
I	(VI)	58,331,397.37	56,519,301.23	37,508,471.39
C				
A				
N				
O	(VII)	752,324.77	806,685.85	
		793,052,845.65	609,602,623.36	542,683,616.75
N				
G				
D				
O				
L	(VIII)	14,000,000.00		
L	(IX)	143,546,246.10	129,847,779.24	97,816,933.76
I				
O	(X)	63,116,852.05	65,812,274.58	57,404,918.27
I				107,804,936.40
F				

Continued
As at December 31, 2022
(Amounts in RMB Yuan)

LIABILITY AND EQUITY	Non-current	December 31, 2022	December 31, 2021	January 1, 2021
			(RMB Yuan)	(RMB Yuan)
Continued:				
Share capital	(XIX)	203,000,000.00	254,050,000.00	312,500,000.00
Reserves				

C **t** **B** **h** **t** A 31 D 2022

LIABILITIES AND EQUITY	NOV	DEC 31, 2022	DEC 31, 2021	JAN 1, 2021
			(RMB)	(RMB)
Current liabilities:				
Short-term borrowings (XXXIII)		74,600,300.00	74,600,300.00	74,600,300.00
Other payables (XXXIV)		855,078,533.30	838,165,395.59	819,509,065.54
Long-term payables (XXXV)		38,399,577.13	38,399,577.13	36,593,228.71
Other payables (XXXVI)		233,506,534.43	257,098,624.31	214,856,099.61
Non-current liabilities:				
Long-term borrowings		1,201,584,944.86	1,208,263,897.03	1,122,247,550.02
Other non-current liabilities		124,317,673.97	72,015,223.54	92,665,008.81
Current liabilities		1,325,902,618.83	1,280,279,120.57	1,214,912,558.83
Other liabilities		2,637,787,406.99	2,377,954,988.76	2,161,261,774.68

TOTAL LIABILITIES AND EQUITY

LIAISON : P : H :
 GUAN W JIN H WANG M

A E'	N XVI	D 31, 2022	D 31, 2021 (R 2)	J 2 1, 2021 (R 2)
------	-------	---------------	-------------------------	--------------------------

资产负债表 截至2022年12月31日 (人民币元)

资产负债表	截至2022年12月31日	截至2021年12月31日	截至2021年12月31日
所有者权益	2022	2021	2021
所有者权益	(人民币元)	(人民币元)	(人民币元)
流动资产：			
货币资金	195,000,000.00	251,050,000.00	310,000,000.00
应收账款			
预付款项			
其他应收款			
存货			
流动资产合计	20,689,401.73	13,161,555.37	34,954,083.13
非流动资产：			
长期股权投资	3,299,924.90	2,011,708.12	
固定资产			3,480,241.45
无形资产	18,740,841.95	17,876,433.39	15,629,765.62
递延所得税资产	597,972.12	4,848,233.63	8,267,930.79
其他非流动资产	49,473,505.95	74,941,835.88	27,298,927.14
非流动资产合计	91,487,500.00	3,000,000.00	
流动资产合计	379,289,146.65	366,889,766.39	399,630,948.13
非流动资产合计			
长期股权投资	284,750,000.00	200,950,000.00	38,000,000.00
固定资产			
无形资产			
递延所得税资产			
其他非流动资产			
非流动资产合计	25,922,687.47		
流动资产合计			
长期股权投资			
固定资产			
无形资产			
递延所得税资产			
其他非流动资产			
非流动资产合计	9,037,891.00	9,341,683.00	9,645,475.00
流动资产合计	2,291,279.89	2,853,156.89	1,607,648.32
非流动资产合计			

LIABILITY AND HOLDERS' EQUITY	December 31, 2022	December 31, 2021	January 1, 2021
(RMB)	(RMB)	(RMB)	(RMB)
Share capital Capital reserve Other comprehensive income Special reserve General reserve Undistributed profits	74,600,300.00 871,230,628.64 38,399,577.13 241,903,691.18	74,600,300.00 854,317,490.93 38,399,577.13 214,974,182.62	74,600,300.00 834,138,174.86 23,311,143.84 36,593,228.71 198,717,046.87
Total	1,226,134,196.95	1,182,291,550.68	1,120,737,606.60
TOTAL LIABILITY AND HOLDERS' EQUITY	1,927,425,201.96	1,762,326,156.96	1,569,621,678.05

The accompanying notes are an integral part of these financial statements.

LIAISON : GUAN W
 PREPARED BY : JIN H
 HEAD OF : WANG M

截至2022年12月31日止年度
财务报表附注
(A 人民币元)

项目	附注	2022年12月31日	2021年12月31日
人民币元		(RMB Y)	(RMB Y)
I. 流动资产		1,484,903,042.25	1,297,430,369.83
货币资金	(XXXVII)	1,484,903,042.25	1,297,430,369.83
II. 非流动资产		1,435,161,133.62	1,226,514,555.85
可供出售金融资产	(XXXVII)	1,131,971,942.77	968,432,455.76
长期股权投资			
对子公司的长期股权投资			
对合营企业的长期股权投资			
对联营企业的长期股权投资			
其他权益工具投资	(XXXVIII)	4,960,285.79	5,754,219.28
其他非流动金融资产	(XXXIX)	15,004,027.73	10,335,392.65
固定资产	(XL)	205,887,172.40	176,371,888.82
在建工程	(XLI)	33,027,987.79	27,962,173.39
无形资产	(XLII)	44,309,717.14	37,658,425.95
开发支出		45,149,998.30	36,267,756.91
商誉		2,761,765.05	1,691,366.88
长期待摊费用	(XLIII)	14,907,710.81	13,619,635.06
递延所得税资产	(XLIV)	2,850,458.27	6,937,845.27
其他非流动资产		-15,926,847.45	-6,565,719.92
III. 流动资产和非流动资产合计		2,919,064,175.87	2,523,944,925.68
IV. 流动负债		16,391,935.00	92,491,794.67
短期借款	(XLIX)	8,553,977.86	11,835,931.80
应付账款	(L)	9,341,038.73	8,636,583.42
V. 非流动负债		15,604,874.13	95,691,143.05
长期借款	(LI)	26,573,712.49	54,830,913.00

C. F. (A. 2022) RMB Y.)
 It N V A. t f. b A. (R.)
 . N t . f t (t t b 1 35825.

附注三 合并现金流量表
 2022年度
 (单位:人民币元)

项目	附注	2022年度	2021年度
一、经营活动产生的现金流量		343,141,450.63	369,798,306.12
销售商品、提供劳务收到的现金	(IV)	265,024,147.50	271,489,388.70
收到的税费返还		154,333.60	3,013,304.93
收到其他与经营活动有关的现金		1,692,773.94	3,068,742.71
购买商品、接受劳务支付的现金		82,345,368.26	70,825,757.20
支付给职工以及为职工支付的现金		18,899,109.47	16,486,961.41
支付的各项税费		16,480,521.45	5,650,976.01
支付其他与经营活动有关的现金		26,568,676.00	19,722,968.32
经营活动产生的现金流量净额		11,229,395.04	14,521,251.32
二、投资活动产生的现金流量		6,245,933.48	5,326,738.38
收回投资收到的现金	(V)	49,902,280.65	4,923,377.54
取得投资收益收到的现金		-5,377,605.11	-3,485,811.81
处置固定资产、无形资产和其他长期资产收回的现金净额		-	-
处置子公司及其他营业单位收到的现金净额		-	-
收到其他与投资活动有关的现金		-	-
投资活动产生的现金流量净额		-2,695,422.53	8,407,356.31

It is not clear whether the N^{+} XVI Ly α emission is produced in the same region as the Ly α emission from the N^{+} V Ly α emission. The Ly α emission from the N^{+} V Ly α emission is produced in the same region as the Ly α emission from the N^{+} V Ly α emission. The Ly α emission from the N^{+} V Ly α emission is produced in the same region as the Ly α emission from the N^{+} V Ly α emission.

. Ob		h		, t f t	
(I) O					
1. C					
2. O					
3. C					
4. C					
(II) O					
1. O					
2. C					
3. A					
4. C					
5. R					
6. E					
7. O					
I. t		h			
				26,929,508.56	
				18,063,484.17	

(I) B (RMB 100)

(II) D (RMB 100)

L ♠ V : P ♣ ♣ ♣ : H ♠ ♠ ♠ :

GUAN W JIN H WANG M

C F 2022 C h E t t t

I		N V		A , t f h A	
I. C h f f t t t					
G				1,452,028,763.13	1,211,114,150.81
N					
N					
N					

Continued from page 100

2022

(A RMB Y)

Item	Unit	Amount	Amount
II. C h f f t t t			
G			52,119,175.58
G		1,650,804.41	7,777,189.35
N			
N		24,100,366.61	8,755,311.37
G			
-t t f h f f t t t		25,751,171.02	68,651,676.30
G			
G		236,910,178.88	178,536,614.68
N			48,600,000.00
N		53,685,701.28	80,564,032.90
G	(LIV)	8,770,704.43	
-t t f h f f t t t		299,366,584.59	307,700,647.58
N t h f f t t t		-273,615,413.57	-239,048,971.28
III. C h f f f t t			
G		9,153,084.38	2,900,000.00
I : G			
G		9,153,084.38	2,900,000.00
G		387,500,000.00	550,250,000.00
G	(LIV)	151,420,250.00	
-t t f h f f f t t		548,073,334.38	553,150,000.00
G			
G		324,220,000.00	428,342,970.00
I : G		51,554,507.56	30,297,107.09
G	(LIV)	56,121,295.37	60,676,565.61
-t t f h f f f t t		431,895,802.93	519,316,642.70
N t h f f f t t		116,177,531.45	33,833,357.30
I. Eff t f f h t h h			
-t t		78,462.87	-38,704.15
. N t h h t		69,861,145.20	-11,357,819.65
A : G	(LV)	188,734,845.77	200,092,665.42
I. C h h t t h f h	(LV)	258,595,990.97	188,734,845.77
T			
L : P : H :			
GUAN W	JIN H	WANG M	

Profit Contribution Statement
For the Year 2022
(All amounts in RMB Yuan)

Item	Number	Amount	Amount
I. Contribution before tax			
Operating income		336,363,866.37	367,674,455.38
Operating expenses		495,591,067.36	804,490,679.80
Operating profit		831,954,933.73	1,172,165,135.18
Operating profit		153,275,777.22	176,137,498.58
Operating profit		147,419,578.70	141,102,134.39
Operating profit		2,393,183.16	9,767,527.34
Operating profit		596,762,811.79	710,127,325.96
Operating profit		899,851,350.87	1,037,134,486.27
Operating profit		-67,896,417.14	135,030,648.91
II. Contribution after tax			
Operating income		12,396,717.38	
Operating expenses		2,298,348.18	7,089,189.35
Operating profit		32,054.56	37,820.00
Operating profit			
Operating profit		14,727,120.12	7,127,009.35
Operating profit		14,643,564.50	37,662,933.95
Operating profit		54,309,855.16	212,313,500.00
Operating profit			
Operating profit		68,953,419.66	249,976,433.95
Operating profit		-54,226,299.54	-242,849,424.60

P 2022
 F 2022
 (A RMB Y)

It	N	A	A
III. C h f f f t t			
Ga V a a		334,500,000.00	518,050,000.00
Ga V		120,000,000.00	
Ga V a a a V			
-t t f h f f t t		454,500,000.00	518,050,000.00
Ga a		306,750,000.00	411,050,000.00
Ga a			
Ga a a		26,512,297.06	19,663,754.20
Ga a a		6,421,875.00	
-t t f h f f t t		339,684,172.06	430,713,754.20
N t h f f f t t		114,815,827.94	87,336,245.80
I . Eff t f f h t h h h			
t		78,462.87	-38,704.15
. N t h h t		-7,228,425.87	-20,521,234.04
A : Ga a a V a a		97,615,570.76	118,136,804.80
I. C h h t t h f h		90,387,144.89	97,615,570.76

T a a a a a a a .

L a V : P a a a : H a a a :
 GUAN W JIN H WANG M

Copyright © 2022
(All rights reserved)

[illegible]

Continuity of Operations For the Year Ended December 31, 2022 (All amounts in RMB Yuan)

Item	Continuity of Operations	Continuity of Operations	Continuity of Operations	Continuity of Operations	Continuity of Operations
(IV) Intangible Assets					
1. Copyrights					
2. Patents					
3. Software					
4. Other Intangible Assets					
(V) Short-Term Investments					
1. Bank Deposits					
2. Other Short-Term Investments					
(VI) Other Assets					
1. Prepaid Expenses					
2. Other Prepaid Expenses					
3. Other Assets					
(VII) Liabilities					
1. Short-Term Debt					
2. Long-Term Debt					
3. Other Liabilities					
(VIII) Equity					
1. Capital Reserve					
2. Surplus Reserve					
3. Other Equity					
(IX) Total Assets					
(X) Total Liabilities and Equity					

Copyright © 2022
(All rights reserved)

[illegible]

WenZhou KangNing Hospital Co., Ltd. 2022 Annual Report
F 2022
(A RMB Y)

Assets	Liabilities	Equity
Current Assets	Current Liabilities	Capital
Non-current Assets	Non-current Liabilities	Reserves
Total Assets	Total Liabilities	Total Equity

WENZHOU KANGNING HOSPITAL CO., LTD.
2022 ANNUAL REPORT
F 2022
(A RMB Y)

I	0	P	P	O	Q	T	L	S	S	R	T
I. B	74,600,300.00				834,138,174.86	23,311,143.84		36,593,228.71	193,286,602.86	1,115,307,162.39	
P : C									5,430,444.01	5,430,444.01	
C											
O											
II. B	74,600,300.00				834,138,174.86	23,311,143.84		36,593,228.71	198,717,046.87	1,120,737,606.60	
III. I											
(I) T					20,179,316.07	-23,311,143.84		1,806,348.42	16,257,135.75	61,533,944.08	
(II) O					20,182,750.66				18,063,484.17	18,063,484.17	
1. C					2,445,056.34				20,182,750.66	20,182,750.66	
2. C										2,445,056.34	
3. A					17,737,694.32					17,737,694.32	
4. O											
(III) D											
1. W									-1,806,348.42	-1,806,348.42	
2. P									1,806,348.42	1,806,348.42	
3. O											
(IV) I											
1. C											
2. C											
3. S											
4. C											
5. C											
6. O											
(V) S											
1. W											
2. U											
(VI) O					-3,434.59	-23,311,143.84				23,307,709.25	
I. B	74,600,300.00				834,137,490.93			38,399,577.13	214,974,182.62	1,182,291,550.68	

T :
L :
GUAN W
P :
JIN H
H :
WANG M

North China Electric Power Group Corporation Limited

Fundamental Data of the Company
(All figures are in RMB Yuan unless otherwise specified)

I. General Information

(I) Company Name

Wenzhou Kangning Hospital Co., Ltd. (Chinese Name)
Wenzhou Kangning Hospital Co., Ltd. (English Name)
PRC F 1996. T C

N **t** **t** **h** **F** **t** **t** **t**
 F 2022
 (A RMB Y)

II. Background







(I) $B \dots f \dots t$

T A S B E
B S , A S A S
B E , A S B E
M F (A S
B E). I , T S E H K L
R G L S T S E H K L
H K C O .

(II) **G**

T

III. S

1. T C 
2. F  , C  , 
3. T C  ,  R P . T  C 

2022 年 12 月 31 日止的期间内，本公司不存在应披露而未披露的重大关联交易。

III. 关联方关系及其交易的披露

(I) 关联方关系及其交易的披露

本公司不存在关联方关系及其交易的披露。

(II) 关联方关系及其交易的披露

本公司不存在关联方关系及其交易的披露。

(III) 关联方关系及其交易的披露

本公司不存在关联方关系及其交易的披露。

(I) 关联方关系及其交易的披露

本公司不存在关联方关系及其交易的披露。

() 关联方关系及其交易的披露

本公司不存在关联方关系及其交易的披露。

T

N **t** **t** **h** **F** **t** **t** **t**

F 2022
(A RMB Y)

III. S $\rightarrow$ $\bar{\nu}_\tau \nu_\tau$ $\rightarrow$ $\bar{\nu}_\tau \nu_\tau$ $\rightarrow$ $\bar{\nu}_\tau \nu_\tau$ ()

(I) P $\frac{t}{f}$ $\frac{t}{f}$ $\frac{t}{t}$ $\frac{t}{(t ,)}$

2. C ()

T
-
-
I
-

(1) I

D R P , C , R P ;

D R P , C

A diagram illustrating a sequence of points and connections. The points are arranged in a roughly horizontal line from left to right, labeled D, R, P, and C. Below D is a point, and below R is a point. Above P is a point, and above C is a point. To the right of C is another point, and below that is another point. Arrows indicate a path starting from D, going down to the point below it, then right to R, then up to P, then left to the point between P and C, then right to C, then up to the point above C, then right to the next point, then down to the point below that, then right to the final point.

Net Profit attributable to the Company's shareholders
F 2022
(A RMB Y)

III. S ()

(I) P. f. f. t t (t,)

2. C ()

(1) I ()

W C
-
W
.

(2) D

G

W C
C
T
O
.



WENZHOU KANGNING HOSPITAL CO., LTD.
2022 ANNUAL REPORT

Wen Zhou Kang Ning Hospital Co., Ltd.
F 2022
(A RMB Y)



Wen Zhou Kang Ning Hospital Co., Ltd.
F 2022
(A RMB Y)

Notes to the Financial Statements
F 2022
(A RMB Y)

III. S ()

() F ()

1. C ()

North E
F 2022
(A RMB Y)

Net Profit attributable to the Company's shareholders
F 2022
(A RMB Y)

III. S ()

() F ()

2. R ()

(3) F ()

F ()
 , ,
 . T
 . T

A ,

Not to be Filled In

F 2022
(A RMB Y)

III. S $\begin{smallmatrix} \bullet & \bullet \\ \bullet & \bullet \end{smallmatrix}$ $\begin{smallmatrix} \bullet & \bullet \\ \bullet & \bullet \end{smallmatrix}$ $\begin{smallmatrix} \bullet \\ \bullet \end{smallmatrix}$ ()



() F t , t (t ,)

2. R ()

(6) $F \rightarrow \dots \rightarrow \dots \rightarrow \dots$

[illegible]

D

A  ,  .

3. D

W, C, and $\mathcal{C}$ are the following:

- T $\frac{1}{2}$ $\frac{1}{2}$ $\frac{1}{2}$ $\frac{1}{2}$;

[illegible]

- T                     

[illegible]

I have been thinking about you a lot lately, and I hope you are doing well. I have been busy with work, but I always find time to think of my friends. I hope you are happy and healthy. I have been thinking about you a lot lately, and I hope you are doing well. I have been busy with work, but I always find time to think of my friends. I hope you are happy and healthy.

N t t h F	t t t
F 2022 (A RMB Y)	)
III. S	()

Ninth Edition

F 2022
(A RMB Y)

III. S

() F $t, t (t,)$

4. D ()

W

$$W = \begin{pmatrix} \begin{pmatrix} 1 & 0 & 0 \\ 0 & 1 & 0 \\ 0 & 0 & 1 \end{pmatrix} & \begin{pmatrix} 0 & 0 & 0 \\ 0 & 0 & 0 \\ 0 & 0 & 0 \end{pmatrix} \\ \begin{pmatrix} 0 & 0 & 0 \\ 0 & 0 & 0 \\ 0 & 0 & 0 \end{pmatrix} & \begin{pmatrix} 0 & 0 & 0 \\ 0 & 0 & 0 \\ 0 & 0 & 0 \end{pmatrix} \end{pmatrix} \quad (1)$$

W C , , , , T . (-) .

5. D ♀ ♀ | ♀ ♀ ♀ ♀ ♀ ♀ ♀ ♀

T
T
. T
. I , C
U

6. T

T C ,

()

 .

G

C

Notes to Financial Statements
F 2022
(A RMB Y)

III. S ()

() F ()

6. T ()

I ,
C ;
 , C 12-
.T

I
 , C
30 , C .U
C

I , C

I - , C

F A S
B E N .14 - R (2017),
 , C

North E
F 2022
(A RMB Y)

Notes to Financial Statements

F 2022
(A RMB Y)

III. S ()

(I)I

1. C
I
I . C
.
2. V
I
3. B
A . W
N
N

Notes to the Financial Statements

F 2022
(A RMB Y)

III. S ()

(I) I ()

4. I
A

5. A
T -

(II) C t t t

1. R
T C . T C
. C
. T C
()

2. D
F



Net Profit attributable to the Company's shareholders
F 2022
(A RMB Y)

III. S ()

(III) L -t , ty t t (t ,)

2. D v

Notes to the Financial Statements

F 2022
(A RMB Y)

III. S ()

(III) L -t , ty t t (t ,)

3. S

(1) L -

L - C
- - . E
C

(2) L -

L - . W G
,
G , . W

T C
- . T
- . I
(O C O , E)
,
T C
O , E
C

Net Profit attributable to the Company's shareholders
F 2022
(A RMB Y)

III. S ()

(III) L -t , ty t t (t ,)

3. S ()

(2) L - ()

U C C ,
C ,
U ,
.

T C -
C -
C () 0.018 GS0 0.. W 0.5 (8 T

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant accounting policies and accounting estimates (continued)

(III) Long-term equity investments (continued)

3. Significant accounting policies and accounting estimates (continued)

(3) Determination of significant influence

When the Company holds 20% or more of the shares of the investee, it is generally considered to have significant influence over the investee. However, if the Company holds less than 20% of the shares, it is also considered to have significant influence over the investee if it has the power to participate in the financial and operating policy decisions of the investee. The determination of significant influence is based on the following factors:

1. The Company holds 20% or more of the shares of the investee.

2. The Company holds less than 20% of the shares, but has the power to participate in the financial and operating policy decisions of the investee.

3. The Company holds less than 20% of the shares, but has the power to appoint or remove members of the board of directors or the management of the investee.

4. The Company holds less than 20% of the shares, but has the power to exercise significant influence over the investee through other means.

When the Company has significant influence over the investee, it shall use the equity method to account for the investment. The equity method is a method of accounting for investments in which the investor has significant influence over the investee. Under the equity method, the investor recognizes its share of the investee's net income or loss and adjusts the carrying amount of the investment accordingly. The equity method is applied to investments in which the investor has significant influence over the investee, regardless of whether the investor holds a majority or minority interest in the investee.

When the Company does not have significant influence over the investee, it shall use the cost method to account for the investment. The cost method is a method of accounting for investments in which the investor does not have significant influence over the investee. Under the cost method, the investor recognizes the cost of the investment and does not adjust the carrying amount of the investment for the investee's net income or loss. The cost method is applied to investments in which the investor does not have significant influence over the investee, regardless of whether the investor holds a majority or minority interest in the investee.

When the Company has significant influence over the investee, it shall also recognize its share of the investee's other comprehensive income or loss and adjust the carrying amount of the investment accordingly. The equity method is applied to investments in which the investor has significant influence over the investee, regardless of whether the investor holds a majority or minority interest in the investee.

When the Company does not have significant influence over the investee, it shall not recognize its share of the investee's other comprehensive income or loss. The cost method is applied to investments in which the investor does not have significant influence over the investee, regardless of whether the investor holds a majority or minority interest in the investee.

When the Company has significant influence over the investee, it shall also recognize its share of the investee's other comprehensive income or loss and adjust the carrying amount of the investment accordingly. The equity method is applied to investments in which the investor has significant influence over the investee, regardless of whether the investor holds a majority or minority interest in the investee.

When the Company does not have significant influence over the investee, it shall not recognize its share of the investee's other comprehensive income or loss. The cost method is applied to investments in which the investor does not have significant influence over the investee, regardless of whether the investor holds a majority or minority interest in the investee.

Notes to the Financial Statements
F 2022
(A RMB Y)

III. S ()

(I) F

1. R
F
(1)
(2)
T
S
G
A
2. D
F
T
F
W

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

III. Significant accounting estimates and assumptions

(I) Financial instruments

2. Derivatives

The Company has not entered into any derivatives contracts for hedging or other purposes. There are no derivatives contracts entered into by the Company.

Contract type	Derivative instrument	Notional amount (RMB Yuan)			Average interest rate (%)
		Derivative instrument	Notional amount (RMB Yuan)	Notional amount (%)	
Bank deposits	Bank deposits	35	5	2.71	
Bank loans	Bank loans	3-10	0-5	9.50-33.33	
Bank borrowings	Bank borrowings	4-10	5	9.50-23.75	
Bank deposits	Bank deposits	3-10	0-5	9.50-33.33	

3. Derivatives

The Company has not entered into any derivatives contracts for hedging or other purposes. There are no derivatives contracts entered into by the Company.

(II) Contractual obligations

The Company has not entered into any contractual obligations for hedging or other purposes. There are no contractual obligations entered into by the Company.

Net Profit attributable to the Company's shareholders

FY 2022
(A RMB Y)

III. S ()

(I) B

1. R

T C
;

A
.

2. G

G
.

G

(1) A
;

(2) B

(3) T
.

G
.

3. G

I
;
3
;
B
.

Notes to the Financial Statements

F 2022
(A RMB Y)

III. Significant accounting policies and accounting estimates

(I) Basic accounting policies

4. Measurement of financial assets and liabilities

F, the company shall measure the financial assets and liabilities at fair value. For financial assets and liabilities measured at fair value, the company shall determine the fair value based on the market price of the financial assets and liabilities in an active market. For financial assets and liabilities measured at fair value, the company shall determine the fair value based on the market price of the financial assets and liabilities in an active market.

F, the company shall measure the financial assets and liabilities at fair value. For financial assets and liabilities measured at fair value, the company shall determine the fair value based on the market price of the financial assets and liabilities in an active market. For financial assets and liabilities measured at fair value, the company shall determine the fair value based on the market price of the financial assets and liabilities in an active market.

D, the company shall measure the financial assets and liabilities at fair value. For financial assets and liabilities measured at fair value, the company shall determine the fair value based on the market price of the financial assets and liabilities in an active market. For financial assets and liabilities measured at fair value, the company shall determine the fair value based on the market price of the financial assets and liabilities in an active market.

(II) Intangible assets

1. Valuation of intangible assets

(1) I, the company shall measure the intangible assets at fair value. For intangible assets measured at fair value, the company shall determine the fair value based on the market price of the intangible assets in an active market.

T, the company shall measure the intangible assets at fair value. For intangible assets measured at fair value, the company shall determine the fair value based on the market price of the intangible assets in an active market. For intangible assets measured at fair value, the company shall determine the fair value based on the market price of the intangible assets in an active market.

(2) S, the company shall measure the intangible assets at fair value. For intangible assets measured at fair value, the company shall determine the fair value based on the market price of the intangible assets in an active market.

T C, the company shall measure the intangible assets at fair value. For intangible assets measured at fair value, the company shall determine the fair value based on the market price of the intangible assets in an active market.

A, the company shall measure the intangible assets at fair value. For intangible assets measured at fair value, the company shall determine the fair value based on the market price of the intangible assets in an active market. For intangible assets measured at fair value, the company shall determine the fair value based on the market price of the intangible assets in an active market.

Notes to Financial Statements
F 2022
(A RMB Y)

III. S ()

(II) I t (t ,)

2. E

E t t

f

It	(y)	A t t b	B
I	40-50	S -	S
S	5	S -	E
C	20-30	S -	E
M	5-20	S -	E
T	10	S -	E

3. S

E C

R : R

D : D

Ninth Edition

F 2022
(A RMB Y)

III. S

$$(II) \quad I_t \quad \dots \quad t \quad (t, \dots)$$


4. C T

T . T

:

(1) I       ;

(2) T C ;

(3) T 

(4) T C $\begin{smallmatrix} \bullet & \bullet \\ \diagdown & \diagup \end{smallmatrix}$ $\begin{smallmatrix} \bullet & \bullet \\ \diagup & \diagdown \end{smallmatrix}$, $\begin{smallmatrix} \bullet & \bullet \\ \diagdown & \diagup \end{smallmatrix}$ $\begin{smallmatrix} \bullet & \bullet \\ \diagup & \diagdown \end{smallmatrix}$
 $\begin{smallmatrix} \bullet \\ \diagdown \end{smallmatrix}$ $\begin{smallmatrix} \bullet & \bullet \\ \diagdown & \diagup \end{smallmatrix}$ $\begin{smallmatrix} \bullet & \bullet \\ \diagdown & \diagup \end{smallmatrix}$, $\begin{smallmatrix} \bullet & \bullet \\ \diagdown & \diagup \end{smallmatrix}$, $\begin{smallmatrix} \bullet & \bullet \\ \diagdown & \diagup \end{smallmatrix}$ $\begin{smallmatrix} \bullet & \bullet \\ \diagup & \diagdown \end{smallmatrix}$ $\begin{smallmatrix} \bullet \\ \diagdown \end{smallmatrix}$;

(5) $T \rightarrow \mathbb{R}^n$ is a $\mathbb{Z}_2$ -equivariant diffeomorphism.

[illegible]

(III) I $t f -t t$

L - , - , , , - , ,
 . I
 ,
 ,
 . T
 , P
 . I
 . A

III. S


$$(III) I \quad \dots \quad t \quad f \quad \dots \quad -t \quad \dots \quad t \quad (\quad t \quad , \quad)$$

G

W
C
, C
. T

O     ,  .

(I) L -t

L - 

() C t t L t

Ninth Edition


F 2022
(A RMB Y)

III. S

(I) E y f t

1. A —

T

W  , C 

W     C                       

2. A - B

(1) C

T C
D
C
I
C
C

Notes to Financial Statements

F 2022
(A RMB Y)

III. Significant Accounting Policies and Accounting Estimates

(I) Basic Accounting Policies

2. Accounting Basis

(2) Depreciation

T C E A W U M . T

T , . I , C

A ,

T . C . U ,

U ,

3. A W C , (): C ; C

Notes to Financial Statements

F 2022
(A RMB Y)

III. S ()

(II) P

T C : ,

(1) C

(2) C

(3)

A

F , W

W , O

I have been thinking about you a lot lately, and I hope you are doing well. I have been busy with work, but I always find time to think about my friends. I hope you are happy and healthy. I have been thinking about you a lot lately, and I hope you are doing well. I have been busy with work, but I always find time to think about my friends. I hope you are happy and healthy.

N t t h F t t t

F 2022
(A RMB Y)

III. S

(III) $h = y(t)$

$$2. \quad G_1 - \begin{array}{c} \bullet \\ | \\ \bullet - \bullet \\ | \quad | \\ \bullet \quad \bullet \end{array} \quad \begin{array}{c} \bullet \\ | \\ \bullet - \bullet \\ | \quad | \\ \bullet \quad \bullet \end{array} \quad \begin{array}{c} \bullet \\ | \\ \bullet - \bullet \\ | \quad | \\ \bullet \quad \bullet \end{array} \quad \begin{array}{c} \bullet \\ | \\ \bullet - \bullet \\ | \quad | \\ \bullet \quad \bullet \end{array}$$
[illegible]

I C $\frac{1}{2}$ $\frac{1}{2}$ $\frac{1}{2}$ $\frac{1}{2}$ $\frac{1}{2}$ - $\frac{1}{2}$ $\frac{1}{2}$ $\frac{1}{2}$



[illegible]

(I)

1. A

T C

I , ,

T C  W , C 

Notes to the Financial Statements

F 2022
(A RMB Y)

III. Significant accounting policies and accounting estimates

(I) Significant accounting policies

1. Assets and liabilities measured at fair value

F , C , I . I , C :

- C , , ,

Notes to Financial Statements

F 2022
(A RMB Y)

III. Significant accounting policies and accounting estimates

() Continued ()

I C ,

A ; ,

F , C

1. T ;

2. T

I - ,

(I) G

1. T

G - C

G C , G

2. T

G C

F 2022
(A RMB Y)

D

2022
 (A) RMB Y)

Ninth Edition

F 2022
(A RMB Y)

III. S $\rightarrow$ $\bar{\nu}_\tau \nu_\tau \nu_\tau$ $\rightarrow$ $\bar{\nu}_\tau \nu_\tau \nu_\tau$ $\rightarrow$ $\bar{\nu}_\tau \nu_\tau \nu_\tau$ ()

$$(\quad \text{III} \text{ D } f \quad t \quad t \quad f \quad t \quad t \quad (\quad t \quad , \quad))$$
[illegible]

- W       
 ;
- W          
           
         
       

(III) $\mathbf{L}$

A $\mathbb{Q}$ -algebra, $\mathcal{A}$, is called *central* if $\mathcal{A} \otimes_{\mathbb{Q}} \mathbb{C} \cong \mathbb{C} \otimes_{\mathbb{Q}} \mathcal{A}$. A $\mathbb{Q}$ -algebra, $\mathcal{A}$, is called *commutative* if $\mathcal{A} \otimes_{\mathbb{Q}} \mathbb{C} \cong \mathbb{C} \otimes_{\mathbb{Q}} \mathcal{A}$. A $\mathbb{Q}$ -algebra, $\mathcal{A}$, is called *simple* if $\mathcal{A} \otimes_{\mathbb{Q}} \mathbb{C} \cong \mathbb{C} \otimes_{\mathbb{Q}} \mathcal{A}$.

[illegible]

I
COVID-19 , C

Notes to the Financial Statements

F 2022
(A RMB Y)

III. Significant accounting policies and accounting estimates

(III) Long-term investments

1. Investment in subsidiaries

(1) Right of control

A subsidiary is an entity that the reporting entity controls. Control is the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities. The reporting entity exercises control over the subsidiary in the following ways: (1) holding the majority of the voting rights; (2) holding the majority of the board of directors; (3) holding the majority of the management rights; (4) holding the majority of the financial and operating decisions.

• The reporting entity holds the majority of the voting rights.

• The reporting entity holds the majority of the board of directors. The board of directors is the highest decision-making body of the subsidiary, and the reporting entity holds the majority of the voting rights.

• The reporting entity holds the majority of the management rights.

• The reporting entity holds the majority of the financial and operating decisions. The reporting entity holds the majority of the voting rights in the subsidiary's financial and operating decisions.

The reporting entity exercises control over the subsidiary in the following ways: (1) holding the majority of the voting rights; (2) holding the majority of the board of directors; (3) holding the majority of the management rights; (4) holding the majority of the financial and operating decisions. The reporting entity exercises control over the subsidiary in the following ways: (1) holding the majority of the voting rights; (2) holding the majority of the board of directors; (3) holding the majority of the management rights; (4) holding the majority of the financial and operating decisions.

The reporting entity exercises control over the subsidiary in the following ways: (1) holding the majority of the voting rights; (2) holding the majority of the board of directors; (3) holding the majority of the management rights; (4) holding the majority of the financial and operating decisions. The reporting entity exercises control over the subsidiary in the following ways: (1) holding the majority of the voting rights; (2) holding the majority of the board of directors; (3) holding the majority of the management rights; (4) holding the majority of the financial and operating decisions.

Ninth Edition

F 2022
(A RMB Y)

III. S

(III) $L = (t, \dots)$
$$1. \quad T \subset C \quad \text{---} \quad \text{---} \quad \text{---} \quad (\quad)$$

(2) $L \cong L$

[illegible]

- [illegible]

T C . I .

T C 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

[illegible]

Notes to the Financial Statements
F 2022
(A RMB Y)

III. S ()

(III) L ()

1. T C ()

(2) L ()

A , , C

A

Notes to the Financial Statements

F 2022
(A RMB Y)

III. Significant accounting policies and accounting estimates

(III) Long-term assets

1. Intangible assets

(4) Land use rights

T C :
:

- : ;
- : .

I , C , - ,
 ,
 .

I , C ,
 - - ,
 . F
 , C
 - -

(5) Research and development expenses of COVID-19

F COVID-19 , C ,
 ,
 . I
 , C , W
 ,
 - ,
 , C

Notes to Financial Statements
F 2022
(A RMB Y)

III. S ()

(III) L (t ,)

1. T C ()

(5) R COVID-19 ()

F - , C . I
 , C ;
 , C

2. T C

A , C
 . A ,
 ()0.5 ()0.366.5 ()0.5 ()0.5 ()0.5

N t t h F		t t t	
F	2022		
(A	RMB Y	)	
III. S			()
(III)			

Notes to the Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

III. Significant accounting policies and accounting estimates

(III) Long-term investments

2. Investment in subsidiaries

(3) Right of control over subsidiaries

- For the purpose of consolidation, the Company identifies subsidiaries based on the definition of "control" in the "Regulations on the Preparation and Presentation of Financial Statements" issued by the Ministry of Finance. Control is defined as the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities. The Company exercises control over its subsidiaries through its majority ownership and the ability to appoint or remove the majority of the members of the board of directors or the equivalent governing body.
- For the purpose of consolidation, the Company identifies subsidiaries based on the definition of "control" in the "Regulations on the Preparation and Presentation of Financial Statements" issued by the Ministry of Finance. Control is defined as the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities. The Company exercises control over its subsidiaries through its majority ownership and the ability to appoint or remove the majority of the members of the board of directors or the equivalent governing body.

Net Profit of the Company for the Year

FY 2022
(A) RMB Y ()

III. S ()

(III) L ()

3. S ()

(2) T C

I - C 2. T
C ; - ,
C , ,
F ,
N III (X) F .

(I) t

T C , ,

A C : (1)
C ; (2)
C ; (3)
C T

() f t t t

T C ,

1. E

A N III. (XXIV), C
T

Notes to Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

III. Significant accounting policies and accounting estimates

(1) Significant accounting policies

2. Earnings per share

A company's earnings per share is calculated as the company's net profit attributable to ordinary shareholders divided by the weighted average number of ordinary shares outstanding during the period. The company's earnings per share is calculated in accordance with the provisions of Article 32 of the Company Law of the People's Republic of China, Article 160 of the Securities Law of the People's Republic of China, and Article 10 of the Measures for the Implementation of the Company Law of the People's Republic of China.

The company's earnings per share is calculated as the company's net profit attributable to ordinary shareholders divided by the weighted average number of ordinary shares outstanding during the period. The company's earnings per share is calculated in accordance with the provisions of Article 32 of the Company Law of the People's Republic of China, Article 160 of the Securities Law of the People's Republic of China, and Article 10 of the Measures for the Implementation of the Company Law of the People's Republic of China.

3. Earnings per share

The company's earnings per share is calculated as the company's net profit attributable to ordinary shareholders divided by the weighted average number of ordinary shares outstanding during the period. The company's earnings per share is calculated in accordance with the provisions of Article 32 of the Company Law of the People's Republic of China, Article 160 of the Securities Law of the People's Republic of China, and Article 10 of the Measures for the Implementation of the Company Law of the People's Republic of China.

4. Management of financial assets and liabilities

In 2022, the company's management of financial assets and liabilities is in accordance with the provisions of the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, and the Measures for the Implementation of the Company Law of the People's Republic of China.

It is the company's policy to manage its financial assets and liabilities in accordance with the provisions of the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, and the Measures for the Implementation of the Company Law of the People's Republic of China.

Item	End of Period	Percentage
Assets	180	
Liabilities	570	
Net assets	10.79%	
Gross profit	60	
Diluted earnings per share	14.00%	
Prior year earnings per share	2.50%	

N t t h F t t t

F 2022
(A RMB Y)

III. S $\rightarrow$ $\mu\mu$ $\rightarrow$ $\mu\mu$ $\rightarrow$ $\mu\mu$ ()

(I) $\partial_{\bar{z}} f = 0$, $f|_D = 0$, $f|_{\partial D} \neq 0$.

I 2021, M F N P D I E
A S N . 15 I 2022 2023, M F N P
D I E A S N . 16 Q&A I
E A S . T C 31
D 2022
Q&A. T C

IV. T₂²

(I) $M \rightarrow \dots \rightarrow t \rightarrow \dots \rightarrow t \rightarrow \dots \rightarrow t \rightarrow \dots \rightarrow t$

1) *How much time do you spend on the Internet?*

VAT = VAT_{gross} / (VAT + 1) T = VAT / (VAT + 1) 3%, 6%, 13%

VAT_{gross} = (T + 1) * VAT VAT_{gross} = (T + 1) * VAT_{gross}

T = VAT_{gross} / (VAT_{gross} + 1)

U			B	VAT		7%
E			B	VAT		5%
E			B			15%, 20%, 25%

C

It is not possible to determine the exact date of the first publication of the book, but it is known that it was published in the early 19th century.

W	K ₂	H	C, L	15%
---	----------------	---	------	-----

Z ♣ J H ♣ T ♠ C 10, L 10 15%

Y K H M C., L. 20%

Notes to the Financial Statements
F 2022
(A RMB Y)

IV. Taxes ()

(II) Profit tax

1. P C O P P
L VAT P B T (C S [2016] N . 36) M F
S T A , C
A M M I (O S C N . 149)
S C I M A M I
(O M H N . 35) M H

Notes to the Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

V. Non-current Assets

(I) Intangible Assets

Item	Original Value	Accumulated Amortization	Book Value
Intangible Assets	454,907.26	971,773.72	

五、非经常性损益对公司净利润的影响

五、非经常性损益对公司净利润的影响

(III) 非经常性损益

1. 非经常性损益明细表

项目	本期发生额	上期发生额
非流动资产处置损益		
计入当期损益的政府补助		
除上述各项之外的其他营业外收入和支出		
其他非经常性损益		
合计	388,961,193.05	303,910,574.15
减：所得税影响额	4,755,919.87	9,812,859.20
减：少数股东权益影响额	3,941,367.25	4,259,870.27
减：其他	5,180,894.08	3,140,407.07
合计	402,839,374.25	321,123,710.69
减：所得税影响额	20,002,683.36	9,365,835.23
合计	382,836,690.89	311,757,875.46

注：非经常性损益是指公司发生的与经营业务无直接关系，以及虽与经营业务相关，但由于其性质、金额或发生频率的影响，预计对财务报表产生较大影响，且从可持续性的角度看，与公司正常经营业务无直接关系，或者虽与正常经营业务相关，但由于其性质特殊或事项特殊，应当在财务报表附注中单独披露的损益。

Notes to the Financial Statements
F 2022
(A RMB Y)

V. N ()

(III) A ()

2. A B B B P P P P

C t y	A , t (%)	A , t (%)	B ,	A (%)	A (%)	B
P						
	18,221,975.88	4.52	12,514,142.66	68.68	5,707,833.22	7,247,978.61
I :						
M	18,221,975.88	4.52	12,514,142.66	68.68	5,707,833.22	7,247,978.61
P						
	384,617,398.37	95.48	7,488,540.70			

Notes to the Financial Statements
F 2022
(A RMB Y)

V. N ()

(III) A ()

2. A ()
P :

It	B	B		P	P	f
		f				
		t		t		f (%)
M		18,221,975.88	12,514,142.66			68.68
						t
						L f t ECL
T		18,221,975.88	12,514,142.66			/

D () : N III. (X)

P :

Item	A	B		P	P	f
		t	t			
On	384,617,398.37		7,488,540.70			1.95
Total	384,617,398.37		7,488,540.70			

C () : N III. (X)

Notes to the Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

V. Notes to the Financial Statements (Continued)

(III) Assets and Liabilities

3. Prepaid expenses	Balance at the beginning of the year	Cash and cash equivalents	Receivables	Other receivables	Prepaid expenses
Prepaid expenses	4,590,286.39	8,289,230.88		365,374.61	12,514,142.66
Prepaid expenses	4,775,548.84	3,379,914.39		666,922.53	7,488,540.70
Total	9,365,835.23	11,669,145.27		1,032,297.14	20,002,683.36
4. Assets					
Intangible assets					Assets
Assets					365,374.61

Notes to the Financial Statements
F 2022
(A RMB Y)

V. N ()

(I) A

1. A

A	B		B	
	A	P	A	P
	(%)		(%)	
W 1	29,973,748.69	93.08	11,751,451.87	99.11
1-2	2,127,484.58	6.61	58,511.20	0.49
2-3	56,690.70	0.18	24,163.99	0.20
Q 3	43,300.00	0.13	24,300.00	0.20
T	32,201,223.97	100.00	11,858,427.06	100.00

附注五 固定资产 2022 年 12 月 31 日余额 人民币元

五. 固定资产 人民币元

(一) 房屋及建筑物

项目	账面原值	账面净值
房屋及建筑物	37,195,219.68	29,925,487.99
合计	37,195,219.68	29,925,487.99

(1) 房屋及建筑物

项目	账面原值	账面净值
房屋及建筑物	31,752,956.09	20,470,501.76
1-2 月	12,384,779.19	4,096,700.18
2-3 月	4,035,447.86	838,693.49
3-4 月	1,755,508.40	2,814,221.11
4-5 月	101,363.87	1,452,266.68
5 月	3,877,306.68	2,930,000.00
合计	53,907,362.09	32,602,383.22
其他	16,712,142.41	2,676,895.23
合计	37,195,219.68	29,925,487.99

Notes to the Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

V. Non-current Assets (Continued)

(1) Other Intangible Assets (Continued)

(2) Other Intangible Assets (Continued)

Category	Book Value at the Beginning of the Year		Additions		Disposals	Decreases		Book Value at the End of the Year	Percentage of Book Value at the End of the Year
	Amount	(%)	Amount	(%)	Amount	Amount	(%)	Amount	(%)
Patent									
Software	25,337,819.20	47.00	15,852,030.91	62.56	9,485,788.29	1,435,560.00	4.40	1,435,560.00	100.00
Intangible Assets									
Hospital									
Unpatented Technology									
Copyright									
Trademark, Patent									
Copyright						1,435,560.00	100.00	1,435,560.00	100.00
Hospital									
Copyright	25,337,819.20	47.00	15,852,030.91	62.56	9,485,788.29				
Patent									
Software	28,569,342.89	53.00	860,111.50	3.01	27,709,431.39	31,166,823.22	95.60	1,241,335.23	3.98
Intangible Assets									
Patent	28,569,342.89	53.00	860,111.50	3.01	27,709,431.39	31,166,823.22	95.60	1,241,335.23	3.98
Total	53,907,362.09	100.00	16,712,142.41	37.19	37,195,219.68	32,602,383.22	100.00	2,676,895.23	29.92

Notes to Financial Statements
F 2022
(A RMB Y)

V. N ()

() Ob (t)

(2) O ()

P V :

N	B	B				P				P				B			
		t		h		f		h		t		f		h			
		P		f		t		f		t		f		h			
								</									

H Y			
H C.,L.	25,337,819.20	15,852,030.91	62.56 h h t

T	25,337,819.20	15,852,030.91	
---	---------------	---------------	--

D P V : P N III. (X)

P V :

N	Ob	B		t h		f h					
		P		f		P		t		f	

P	28,569,542.89	860,111.50	3.01
---	---------------	------------	------

T	28,569,542.89	860,111.50	
---	---------------	------------	--

C P V : P
N III. (X)

Notes to the Financial Statements
For the year ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

V. Non-current assets

(1) Other non-current assets

(3) Details of other non-current assets

Particulars	12-month ECL	Lifetime ECL (12-month ECL)	Lifetime ECL (Lifetime ECL)	Total
Bank deposits	1,241,335.23		1,435,560.00	2,676,895.23
Bank deposits				
Prepaid expenses				
- Trade receivables				
- Trade payables				
- Receivables				
- Receivables				
Prepaid expenses	141,793.04		15,852,030.91	15,993,823.95
Receivables	485,492.80		1,435,560.00	1,921,052.80
Wages	37,523.97			37,523.97
Wages				
Other				
Bank deposits	860,111.50		15,852,030.91	16,712,142.41

Notes to Financial Statements
F 2022
(A RMB Y)

V. N ()

() Ob (t r)

(3) D ()

C :

B	12- ECL	t 1 ECL	t 2 L ^f t ECL (t t- (t t-))	t 3 L ^f t ECL (t t- (t t-))	t
B		31,166,823.22		1,435,560.00	32,602,383.22
B					
- T	2				
- T	3				
- R	2				
- R	1				
A		2,428,909.82		25,337,819.20	27,766,729.02
D		4,306,570.80		1,435,560.00	5,742,130.80
O		-719,619.35			-719,619.35
B		28,569,542.89		25,337,819.20	53,907,362.09

Notes to the Financial Statements
F 2022
(A RMB Y)

V. N ()

() Ob (t r)

(4) P , ,

C t y	B a a	C a	R W - a	B t f b
P	1,435,560.00	15,852,030.91	1,435,560.00	15,852,030.91
P	1,241,335.23	141,793.04	485,492.80	37,523.97
T	2,676,895.23	15,993,823.95	1,921,052.80	37,523.97
				16,712,142.41

O , a a , a a a a a :

D t b f
t t f
N f t b

H a U a C	1,435,560.00	F	R W M a a
a C D			a a
A T , P a C a			
T	1,435,560.00		

Notes to Financial Statements
For the year ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

V. Non-current assets

(1) Other non-current assets

(5) Other non-current assets

Item	Amount
Other non-current assets	37,523.97

(6) Other non-current assets

Item	Amount	Amount
Depreciation	20,677,631.31	23,577,997.61
Prepaid expenses	816,666.30	4,228,330.66

五、非经常性损益
 非经常性损益是指公司发生的与经营业务无直接关系，以及虽与经营业务相关，但由于其性质、发生频率、影响大小、不能按常规营业周期来核算的损益。

五、非经常性损益明细表

(一) 其他非经常性损益

项目	本期发生额	上期发生额	本期发生额	本期发生额
其他非经常性损益	3,697,607.74	3,697,607.74	2,242,027.51	2,242,027.51
其他非经常性损益	54,633,789.63	54,633,789.63	54,277,273.72	54,277,273.72
其他非经常性损益	58,331,397.37	58,331,397.37	56,519,301.23	56,519,301.23

(二) 其他非经常性损益

项目	本期发生额	本期发生额
其他非经常性损益	196,008.48	137,228.50
其他非经常性损益	269,072.88	321,191.35
其他非经常性损益	287,243.41	348,266.00
其他非经常性损益	752,324.77	806,685.85

Notes to the Financial Statements
F 2022
(A RMB Y)

V. N ()

(III) L

B		B		B		B		B		D	
P		P		P		P		P		P	
It		B		t		B		B		B	
E		14,000,000.00		14,000,000.00							
T		14,000,000.00		14,000,000.00							

(I) L -t , ty t t

I		I		I		I		I		I	
A		A		A		A		A		A	
M T C.,L.		13,156,356.09		-4,287,437.64		5,310,451.69		14,179,350.14			
Y H C.,L.		58,100,000.00		500,000.00				57,600,000.00			
H M C.,L.		22,193,790.14		-1,090,147.47				21,103,642.67			
M C C.,L.		23,198,356.89		-1,102,416.10				22,095,940.79			
K H C.,L.		18,687,211.65		74,969.38		400,000.00		18,362,181.03			
C Y H C.,L.		11,514,784.92		-1,309,633.45				10,205,151.47			
J Y S H C.,L.		5,191,069.69						5,191,069.69			
H Y H C.,L.											
(N)											
T		129,847,779.24		22,193,790.14		500,000.00		-7,714,705.28		5,310,451.69	
								400,000.00		5,191,069.69	
										143,546,246.10	

N : O 10 A 2022, Z K H M (G) C., L. () Z K), C 28% H Y H C., L. () H Y), , T W L L Y H M C., L. () L L) RMB14,000,000.00, S A C J H G S I E I F P (L.P.), C J P II M H S I E I F P (L.P.), T W L L H M C., L., L L L , RMB13,922,929.38 , Z K , H Y 33% , H Y B , H Y C Y H Y

V. N. ()

() Oh - , , t f t

	B	B
It		
F	63,116,852.05	65,812,274.58
I	63,116,852.05	65,812,274.58
T	63,116,852.05	65,812,274.58

V. N		()		()		F		F	
() F		()		()		()		()	
2. D		()		()		()		()	
It		B		M		E		F	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	
		t		t		t		t	

Wenzhou Kangning Hospital Co., Ltd.
2022 Annual Report

V. N ()

(I F)

2. D ()

Item	Balance at the beginning of the year	Change	Balance at the end of the year	Change	Balance at the end of the year
2. A					
(1) B	97,583,529.57	93,448,930.55	2,620,876.20	47,139,318.33	240,792,654.65
(2) I	21,780,272.36	23,765,333.80	3,918,211.31	9,282,744.01	125,367,546.38
- P	21,780,272.36	21,259,481.17	1,035,359.81	8,378,127.80	53,029,785.07
- I		2,505,852.63	2,882,851.50	904,616.21	6,293,320.34
- O					66,044,440.97
(3) D	12,029,010.56	48,647,077.77	1,557,788.21	19,170,037.34	81,403,913.88
- D		6,650,418.76	620,766.50	1,300,387.75	8,571,573.01
- D	1,654,288.20	3,475,806.87	214,904.65	1,442,900.18	
- O	10,374,722.36	38,520,852.14	722,117.06	16,426,749.41	66,044,440.97
(4) B	107,334,791.37	68,567,186.58	4,981,299.30	37,252,025.00	284,756,287.15
3. I					
(1) B					
(2) I					
(3) D					
(4) B					
4. C					
(1) C	569,040,155.66	33,243,560.03	4,421,894.49	14,908,581.66	695,020,440.79
(2) C	648,250,430.33	48,769,190.23	3,927,848.67	20,899,302.29	721,846,771.52

五、非经常性损益明细表
 附：非经常性损益明细表
 2022
 (A 人民币元)

V. Non-recurring损益 (人民币元)

(II) 非经常性损益

1. 非经常性损益

Item	Amount	Amount
Other income	152,497,399.68	43,795,718.15
Other income	152,497,399.68	43,795,718.15

2. 非经常性损益

Item	Amount	Amount	Amount	Amount
Wen Kang Ning Hospital	311,600.00	311,600.00	782,356.00	782,356.00
Tongshan Hospital			1,027,373.54	1,027,373.54
Tongshan Hospital	72,377,326.40	72,377,326.40	6,213,670.10	6,213,670.10
Tongshan Hospital			7,504,860.00	7,504,860.00
Tongshan Hospital			27,288,058.64	27,288,058.64
Tongshan Hospital	27,536,449.81	27,536,449.81	150,609.00	150,609.00
Tongshan Hospital	16,073,697.42	16,073,697.42		
Tongshan Hospital	35,508,167.99	35,508,167.99		
Other	690,158.06	690,158.06	828,790.87	828,790.87
Total	152,497,399.68	152,497,399.68	43,795,718.15	43,795,718.15

V. N
(III)C
3. M

N t t b F									
F 2022									
(A RMB Y)									
P t	B t	B t	B t	B t	B t	B t	B t	B t	B t
T	L Y H	P C H	O Y H	T	L C	H	T	H	T
	18,003.00	6,213,670.10	66,247,515.67	72,461,185.77	40.25	40.00	1,883,479.17	1,608,608.70	4.90
	1,897.75	7,504,860.00	17,107,073.00	24,611,933.00	100.00	100.00			0
	4,047.80	27,288,038.64	11,021,933.76	38,310,012.40	100.00	100.00			0
	16,020.00	150,609.00	27,385,940.81	27,536,449.81	17.19	20.00			0
	9,848.00		16,073,697.42	16,073,697.42	16.32	15.00			0
	6,666.00	35,508,167.99		35,508,167.99	54.15	55.00			0
	41,157,197.74	173,344,248.65	62,921,945.40	151,579,500.99			1,883,479.17	1,608,608.70	

Notes to the Financial Statements
F 2022
(A RMB Y)

V. N ()

(III) h t- f- t

It	B	
	t t	t
1.O		
(1)B	363,270,419.51	363,270,419.51
(2)I	37,254,480.17	37,254,480.17
- N	21,847,297.56	21,847,297.56
- I	15,407,182.61	15,407,182.61
(3)D	81,876,743.78	81,876,743.78
- D	16,772,968.78	16,772,968.78
- D	65,103,775.00	65,103,775.00
(4)B	318,648,155.90	318,648,155.90
2.A		
(1)B	105,858,149.38	105,858,149.38
(2)I	38,189,335.84	38,189,335.84
- P	38,189,335.84	38,189,335.84
(3)D	15,803,080.90	15,803,080.90
- D	4,949,246.94	4,949,246.94
- D	10,853,833.96	10,853,833.96
(4)B	128,244,404.32	128,244,404.32
3.I		
(1)B		
(2)I		
(3)D		
(4)B		
4.C		
(1)C	190,403,751.58	190,403,751.58
(2)C	257,412,270.13	257,412,270.13

Notes to the Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

V. Non-current Assets

(I) Intangible Assets

Item	Land Use Rights		Patent Rights		Software		Other Intangible Assets	
	Original Value	Accumulated Depreciation	Original Value	Accumulated Depreciation	Original Value	Accumulated Depreciation	Original Value	Accumulated Depreciation
1.0 Land Use Rights								
(1) Land Use Rights	102,977,820.17	3,061,637.13	14,252,889.08	129,837,000.00	32,400,000.00	282,529,346.38		
(2) Intangible Assets	25,616,355.88		-3,433,306.28	29,000,000.00		51,183,049.60		
- Patent Rights	19,841,690.88		-4,460,006.28			15,381,684.60		
- Land Use Rights	5,774,665.00		1,026,700.00	29,000,000.00		35,801,365.00		
(3) Depreciation			1,141,970.00			1,141,970.00		
- Depreciation			508,000.00			508,000.00		
- Depreciation			633,970.00			633,970.00		
(4) Land Use Rights	128,594,176.05	3,061,637.13	9,677,612.80	158,837,000.00	32,400,000.00	332,570,425.98		
2.A Land Use Rights								
(1) Land Use Rights	9,610,253.66	360,120.18	9,441,245.79	27,772,369.86	7,353,571.43	54,537,560.92		
(2) Intangible Assets	2,889,207.41	330,465.48	1,799,113.48	17,315,075.42	1,500,000.00	23,833,861.79		
- Patent Rights	2,889,207.41	330,465.48	1,072,248.57	17,315,075.42	1,500,000.00	23,106,996.88		
- Land Use Rights			726,864.91			726,864.91		
(3) Depreciation			485,345.23			485,345.23		
- Depreciation			39,066.67			39,066.67		
- Depreciation			446,278.56			446,278.56		
(4) Land Use Rights	12,499,461.07	690,585.66	10,755,014.04	45,087,445.28	8,853,571.43	77,886,077.48		
3.I Land Use Rights								
(1) Land Use Rights								
(2) Intangible Assets								
(3) Depreciation								
(4) Land Use Rights								
4.C Land Use Rights								
(1) Land Use Rights	116,094,714.98	2,371,051.47	-1,077,401.24	113,749,554.72	23,546,428.57	254,684,348.50		
(2) Land Use Rights	93,367,566.51	2,701,516.95	4,811,643.29	102,064,630.14	25,046,428.57	227,991,785.46		

Notes to the Financial Statements
F
(A) 2022
RMB Y ()

B
t
f
b

D

()

()

I

B
t
t
t
t

t

t

t

t

V. N
() G
1. C

N
f
t

Wen Zhou Kang Ning Hospital Co., Ltd.
F 2022
(A RMB Y)

V. N ()

() G ()

2. I

A C ;

U : RMB'0,000

A 31 D 2022

N Y H C.,L .	927.18
H Y P H C.,L .	69.03
G Y H C.,L .	154.90
W N P S H C.,L .	778.49
B Y H C.,L .	2,298.73
W Y H T C.,L .	15.11
H K H C.,L .	506.9
C K P H C.,L .	684.33
W C H C.,L .	1,941.63
P C Y H C.,L .	5,177.02
H Y N S C.,L .	127.26
Z F N T C.,L .	32.60
J S H C.,L .	506.03

T 13,219.21

I , C ; I

Ninth Edition

F 2022
(A RMB Y)

V. N. ()

$$(\quad) \text{ G} \quad \dots \quad (\quad \text{ t , } \quad)$$

3. P $\rightarrow$ Q , $R \rightarrow Q$ $\vdash$ $R \rightarrow P$

y t f t t t

A...

A - t t

f v

$$t = (1/\sqrt{1-v^2/c^2})$$

A t t r i b u t e	f r e q u e n c y	P e r c e n t a g e	N u m b e r	P e r c e n t a g e
N o n - Y e a r H i g h S c h o o l	219	337	2.50%	21.33%
H i g h S c h o o l Y e a r P o s t - H i g h S c h o o l	267	289	2.50%	20.60%
G r a d u a t e Y e a r H i g h S c h o o l				
W o r k N o n - P o s t S e n i o r H i g h S c h o o l	323	291	2.50%	22.06%
B o r n Y e a r H i g h S c h o o l	32	1,810	2.50%	-2.40%
W o r k Y e a r H i g h T e c h n i c a n C o l l e g e				
H i g h S c h o o l K e e p H i g h S c h o o l	211	196	2.50%	16.94%
C o l l e g e K e e p P o s t H i g h S c h o o l	315	205	2.50%	17.48%
W o r k C o l l e g e H i g h S c h o o l	325	546	2.50%	9.59%
C o l l e g e K e e p H i g h S c h o o l H i g h S c h o o l	213	400	2.50%	19.01%
P o s t C o l l e g e Y e a r H i g h S c h o o l	425	594	2.50%	6.71%
P o s t Y e a r H i g h S c h o o l H i g h S c h o o l	270	273	2.50%	15.82%
H i g h S c h o o l Y e a r N o n - S e n i o r C o l l e g e	72	117	2.50%	21.92%
J u n i o r S e n i o r H i g h S c h o o l	382	284	2.50%	22.65%

0 3 3 :

1. 在“**数据源**”列表框中，单击“**数据表**”按钮，打开“**数据源**”任务窗格。

V. N. ()

$$() \mathbf{G} \quad (\mathbf{t} ,)$$

4. $I \rightarrow I$

I 2022, B Y H C ., L . D COVID-19, C RMB10,345,460.56 .

(I) L -t

	Bilan	Impôts	A	O	Bilan
It					
R	150,328,412.40	100,049,601.67	46,186,845.31	14,777,100.83	189,414,067.93
L	172,625.00	94,613.90	94,967.96		172,270.94
T	150,501,037.40	100,144,215.57	46,281,813.27	14,777,100.83	189,586,338.87

(II) D^f t t f t t

1. D

Item	Budgetary Control		Budgetary Control	
	Budgetary Control		Budgetary Control	
	Debit	Debit	Debit	Debit
Purchase of goods	16,979,155.87	3,164,380.59	8,026,079.93	1,687,621.09
Debit	50,169,236.15	8,217,114.53	18,012,806.84	4,503,201.71
Debit	4,390,510.38	1,097,627.60	4,653,187.96	1,163,296.99
Salaries	54,688,502.33	8,203,275.35	46,552,302.33	6,982,845.35
Total	126,227,404.73	20,682,398.07	77,244,377.06	14,336,965.14

Notes to the Financial Statements
F 2022
(A RMB Y)

V. N ()

(II) D f t f t (t)

2. D

It	B t h f h	B a a	T a	D f t D
A	148,564,631.76	37,141,157.94	144,340,394.12	36,085,098.53
C	13,116,852.07	1,967,527.81	15,812,274.60	2,371,841.19
O	6,620,111.12	1,439,193.06	6,958,909.45	1,418,850.23
T	168,301,594.95	40,547,878.81	167,111,578.17	39,875,789.95

(III) Ob - t t

I	B t h f h	B a a	P f C y	P	G y
P	6,936,000.00	6,936,000.00	6,936,000.00		6,936,000.00
P	6,605,047.21	6,605,047.21	130,386.60		130,386.60
T			14,000,000.00		14,000,000.00
T	13,541,047.21	13,541,047.21	21,066,386.60		21,066,386.60

(I) h t-t

It	B t h f h	B a a
S	195,000,000.00	200,000,000.00
G	8,000,000.00	54,050,000.00
T	203,000,000.00	254,050,000.00

Notes to the Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

V. Non-current Assets

(1) Intangible Assets

Item	Balance at the beginning of the year	Increases during the year	Decreases during the year	Balance at the end of the year
Patent rights		13,922,929.38		13,922,929.38
Total		13,922,929.38		13,922,929.38

(2) Long-term Equity Investments

Item	Balance at the beginning of the year	Increases during the year	Decreases during the year	Balance at the end of the year
Long-term equity investments		997,944.00		997,944.00
Total		997,944.00		997,944.00

(3) Available-for-sale Financial Assets

The available-for-sale financial assets are measured at fair value.

Item	Balance at the beginning of the year	Increases during the year	Decreases during the year	Balance at the end of the year
Available-for-sale financial assets		84,193,738.77	55,761,620.69	28,432,118.08
Available-for-sale financial assets		1,161,389.02	2,767,905.77	884,483.25
Available-for-sale financial assets		71,968.47	168,509.77	3,418.70
Available-for-sale financial assets		345,965.27	287,110.78	58,854.49
Total		86,373,061.53	58,819,146.93	27,553,914.60

Total

附注五、非流动资产

截至2022年12月31日，非流动资产账面价值为人民币16,275,602.70元。

五、非流动资产

(三) 长期股权投资

项目	账面价值	账面余额
It	h	h
长期股权投资	29,436,207.46	16,275,602.70
长期股权投资减值准备	458,629.04	
合计	29,894,836.50	16,275,602.70

(一) 长期股权投资

项目	账面价值	账面余额
It	h	h
长期股权投资		3,240.59
合计		3,240.59

(二) 长期股权投资减值准备

1. 长期股权投资减值准备

项目	账面余额	已计提减值准备	账面价值
It	h	h	h
长期股权投资	57,969,287.42	498,871,976.49	488,702,553.33
长期股权投资减值准备	2,518,896.85	30,311,176.43	30,410,434.15
合计	60,488,184.27	529,183,152.92	519,112,987.48

Notes to the Financial Statements
F 2022
(A RMB Y)

V. N ()

() E f t y (t ,)

2. L -

Item	Balance at the beginning of the year	Increase	Decrease	Balance at the end of the year
(1) Wages, salaries, bonuses, etc.	56,230,979.61	447,906,594.96	437,976,426.00	66,161,148.57
(2) Social security	87,835.30	10,184,665.65	9,965,118.81	307,382.14
(3) Short-term employee benefits	1,334,394.89	19,527,025.66	19,397,236.12	1,464,184.43
I : Medical insurance	1,290,685.28	18,813,797.48	18,678,735.17	1,425,747.59
Welfare fund	38,841.61	641,567.33	643,107.24	37,301.70
Housing fund	4,868.00	55,652.85	60,096.21	424.64
O		16,008.00	15,297.50	710.50
(4) Housing				

附注五 递延所得税资产和递延所得税负债

截至2022年12月31日，本公司无递延所得税资产和递延所得税负债。

五、非经常性损益

(一) 非经常性损益明细表

项目	本期发生额	上期发生额
非流动资产处置损益	2,399,813.52	2,194,179.27
公允价值变动损益	26,859,279.46	22,060,348.34
计入当期损益的政府补助	1,260,918.02	1,102,372.67
除金融资产以外的其他权益工具投资公允价值变动	163,205.29	39,305.94
其他	2,292,516.47	4,544,055.56
非经常性损益合计	116,587.33	28,135.83
所得税费用	387,329.69	250,083.20
非经常性损益净额	25,663.04	16,848.52
其他	1,696.00	

Notes to the Financial Statements
For the year ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

V. Non-current assets (continued)

(III) Other non-current assets (continued)

2. Development costs

Item	Balance at the beginning of the year	Balance at the end of the year
Original value		
Development costs	735,000.00	86,550.00
Total	735,000.00	86,550.00

3. Other non-current assets

Item	Balance at the beginning of the year	Balance at the end of the year
Patent rights	25,932,146.03	8,703,936.40
Patent rights	7,000,000.00	15,000,000.00
Work in progress	3,682,272.62	7,166,038.37
Development costs	1,900,552.80	1,094,722.20
Construction in progress	17,695,375.57	7,496,808.30
Prepaid expenses	4,374,261.21	4,312,000.00
Assets held for sale	3,673,024.53	6,981,466.40
Other non-current assets	6,624,054.06	4,025,654.97
Total	70,881,686.82	54,780,626.64

Notes to the Financial Statements
F 2022
(A RMB Y)

V. Non-current Assets ()

(III) Non-current Assets

Item	Balance at the end of the reporting period	Balance at the beginning of the reporting period
Long-term equity investments	22,470,000.00	18,200,000.00
Long-term receivables	99,580,000.00	
Long-term prepaid expenses	25,548,324.39	30,040,752.22
Total	147,598,324.39	48,240,752.22

(I) Long-term equity investments

Item	Balance at the end of the reporting period	Balance at the beginning of the reporting period
Long-term equity investments		

五、非经常性损益明细表
 附注 2022
 (A 人民币元)

V. N ()

(I) L -t y

It	B t f	B a a
L -	42,404,938.54	
S		
T	42,404,938.54	

O : -

It	B t f	B a a
A	141,984,938.54	
I : U	9,382,772.07	
L : L -	99,580,000.00	
T	42,404,938.54	

(II) D f

It	B a a	I a	D a	B t f	R a
G	9,341,683.00		303,792.00	9,037,891.00	

Notes to the Financial Statements
F 2022
(A RMB Y)

V. N ()

(III) D f (t r)

P : A

	Balance at the beginning of the year	Change	Balance at the end of the year	
L				A - /
Exp	9,341,683.00	303,792.00	9,037,891.00	A -
T	9,341,683.00	303,792.00	9,037,891.00	

(III) h t

	Balance at the beginning of the year	Change (+)/(-)	Balance at the end of the year	
It				h f
T	74,600,300.00		74,600,300.00	

(I) C t r

	Balance at the beginning of the year	Change	Balance at the end of the year	
It				h f
S	783,420,735.87		783,420,735.87	
O				
- S -	32,642,955.35	12,214,418.85	44,857,374.20	
- O	22,101,704.37	4,698,718.86	26,800,423.23	
T	838,165,395.59	16,913,137.71	855,078,533.30	

Notes to the Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

V. Notes to the Financial Statements (Continued)

(I) Cash and cash equivalents

On December 31, 2022, the Company's cash and cash equivalents were RMB4,698,718.86.

(1) For the year ended December 31, 2022, the Company's cash and cash equivalents were RMB4,698,718.86.

(2) In 2022, the Company's cash and cash equivalents were RMB4,698,718.86. The Company's cash and cash equivalents were RMB4,698,718.86 at the end of the year.

(II) Accounts receivable

Item	Balance at the beginning of the year	Balance at the end of the year	Change
Accounts receivable	38,399,577.13	38,399,577.13	38,399,577.13
Total	38,399,577.13	38,399,577.13	38,399,577.13

On December 31, 2022:

The Company's accounts receivable are classified into two categories: accounts receivable and accounts receivable. The Company's accounts receivable are classified into two categories: accounts receivable and accounts receivable. The Company's accounts receivable are classified into two categories: accounts receivable and accounts receivable.

North E
F 2022
(A RMB Y)

Wen Zhou Kang Ning Hospital Co., Ltd.
F 2022
(A RMB Y)

V. N ()

(III)

1. A

Item	A	C	A	C
Ma	1,366,816,938.51	1,040,114,649.97	1,202,774,377.74	897,111,635.75
O	118,086,103.74	91,857,292.80	94,655,992.09	71,320,820.01
T	1,484,903,042.25	1,131,971,942.77	1,297,430,369.83	968,432,455.76

B :

Item	A	A
R	1,366,816,938.51	1,202,774,377.74
I : P	305,118,303.27	267,588,282.25
T	1,061,698,635.24	935,186,095.49
R	118,086,103.74	94,655,992.09
I : W	85,464,736.39	51,613,429.22
M	3,000,000.00	2,970,297.00
R	8,067,969.32	7,515,329.40
R		16,043,547.63
O	21,553,398.03	16,513,388.84
T	1,484,903,042.25	1,297,430,369.83

2. D

T ,

Notes to the Financial Statements
F 2022
(A RMB Y)

V. N ()

(III) h

It

A , t f b A
t t

Notes to the Financial Statements
F 2022
(A RMB Y)

V. N ()

(L)G

Item	Amount	Amount
E	106,839,736.87	92,095,322.35
C	22,821,067.41	11,791,502.03
D	12,364,390.29	10,327,372.91
R	7,928,268.21	7,688,976.40
A	7,169,511.48	7,803,052.34
A	6,366,300.00	1,222,900.00
O	5,452,608.66	5,171,123.31
A	5,226,706.30	3,986,627.45
E	4,539,506.45	2,946,383.00
E	4,412,652.14	8,414,462.03
T	4,358,637.42	2,835,174.29
P	2,798,524.34	3,204,882.36
H	2,653,266.15	4,644,062.36
G	2,527,587.52	3,580,020.08
P	2,521,353.37	1,319,556.59
O	2,099,610.09	3,313,286.64
U	1,889,937.19	1,974,023.35
P		96,657.59
O	3,917,508.51	3,956,503.74
T	205,887,172.40	176,371,888.82

Notes to the Financial Statements
F 2022
(A RMB Y)

V. N ()

(LI) h t

Item	Amount	Amount
E	29,575,455.47	24,627,424.22
O	1,164,368.95	1,346,035.33
D	550,065.23	594,882.24
P	400,114.92	311,882.70
A	76,467.92	
T	68,877.00	134,907.60
C	58,690.00	
T	30,200.00	
T	19,682.96	76,999.34
U	11,090.48	
C	3,000.00	
O	1,069,974.86	870,041.96
T	33,027,987.79	27,962,173.39

(LII) F

Item	Amount	Amount
I	45,149,998.30	36,267,756.91
I : I	11,935,506.62	14,290,203.16
L : I	2,761,765.05	1,691,366.88
F	-78,462.87	38,704.15
F	1,999,946.76	3,043,331.77
T	44,309,717.14	37,658,425.95

Notes to the Financial Statements
 For the year ended December 31, 2022
 (All amounts in RMB Yuan, unless otherwise specified)

V. Non-current assets (continued)

(LIII) Other non-current assets

Item	Amount at the end of the year	Amount at the beginning of the year
Goodwill	14,602,195.91	13,486,446.80
Intangible assets (including VAT)	37,171.75	
Financial assets	162,213.15	133,188.26
Other non-current assets	106,130.00	
Total	14,907,710.81	13,619,635.06

Goodwill

Item	Amount at the end of the year	Amount at the beginning of the year	Change
Intangible assets	859,807.09	1,231,900.37	I - 372,093.28
Software	3,408,933.78	3,325,154.99	I - 83,778.79
Software	1,018,900.00	2,270,000.00	I - 1,251,100.00
Software			
Software	973,813.11	244,079.31	I - 729,733.80
Software			
Software	638,519.98		I - 638,519.98
Software	600,000.00	50,000.00	I - 550,000.00
Software	600,000.00		I - 600,000.00
Software	440,197.00	814,795.52	I - 374,598.52
Software	311,520.00	744,608.99	I - 433,088.99
Software			
Software	303,792.00	303,792.00	A - 0.00
Software	300,000.00		I - 300,000.00
Software	284,000.00	284,000.00	I - 0.00
Software	249,000.00		I - 249,000.00
Software			
Software	238,400.00		I - 238,400.00

Notes to the Financial Statements
附注
F 2022
(A RMB Y)

V. N ()

(LIII) Ob ()

G ()

Item	Amount	Amount	Amount /
H COVID-19			
H C P	197,750.00		I -
H C C	174,653.70		I -
U S B B H R			
S S	138,796.96		I -
O S	120,835.00		I -
S	117,625.00		I -
W - D H			
S C	64,000.00		I -
H B Y D ,H	63,971.59		I -
I			
D R B P	55,332.00	50,000.00	I -
S I P	50,000.00		I -
S	90,000.00	168,696.99	I -
S D P ' H	40,000.00	40,000.00	I -
T M F S A T			
	38,201.19		I -
E	36,218.55		I -
T 2022			
E I B Y C	22,045.69		I -
S F B N M B P A	20,000.00		I -
T - P B			
W E E B	20,000.00		I -
T -			
H C L D	20,000.00		I -
T - C B			
W E E B	20,000.00		I -

Notes to the Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

V. Non-current Assets

(III) Other Non-current Assets

Other Non-current Assets (in RMB Yuan)

Item	Amount at the end of the year	Amount at the beginning of the year	Change
Receivables from related parties			
D.C. P.V.	17,000.00		I -
Share of profit or loss of equity method investees			
E.C. J.D.	13,610.61		I -
W.L.D.D. R.B.E			
R.I.P.	12,000.00		I -
Y.C.H.B.S. P.H.S.F	10,200.00	13,500.00	I -
W.M.H.C. F.Y.M.			
T.	7,000.00		I -
W.M.H.C. H.R.			
T.F	6,700.00		I -
S.W.H.P.F.M.C	4,433.33		I -
P.C.H.B.S.F	3,000.00	1,904,299.94	I -
L.C.C.D.C.P.F.M			
S.	3,000.00		I -
W.H.P.F.M.C.H			
P.F.S	1,833.33		I -
Y.D.P.D.F.R			
C.R., D.B.	1,600.00		I -
E.A.S.	1,500.00	74,237.34	I -
M.S.	1,380.00		I -
P.H.S.F.L.D.H.C	1,000.00		I -
P.C.P.F.E.M.-C			
T.HIV,S.H.B	476.00		I -
P.C.P.F.F.P.B.D			
P.	450.00		I -
O.D.M.S.A.S.			
M.A.D.R.	360.00		I -

North E
F 2022
(A RMB Y)

Notes to the Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

V. Non-current assets

(I) Goodwill

Item	Amount at the end of the period	Amount at the beginning of the period
Initial recognition		
Goodwill	-2,054,396.53	8,407,356.31
Goodwill impairment		
Goodwill impairment loss	-13,922,929.38	
Goodwill impairment reversal		1,010,034.42
Total	-15,977,325.91	9,417,390.73

(II) Intangible assets

Item	Amount at the end of the period	Amount at the beginning of the period
Initial recognition		
Intangible assets	11,260,563.08	3,005,695.74
Intangible assets impairment	13,930,978.11	-865,499.29
Total	25,191,541.19	2,140,196.45

(III) Assets held for sale

Item	Amount at the end of the period	Amount at the beginning of the period
Initial recognition		
Assets held for sale	10,345,460.56	6,179,290.37
Total	10,345,460.56	6,179,290.37

五、非经常性损益明细表
 2022年度
 (A股) (人民币元)

V. Non-recurring损益 (人民币元)

(L III) 非经常性损益

A

-

Item	Amount	Amount	Amount
Government grants	406,184.95	-101,512.90	406,184.95
Other non-recurring income	406,184.95	-101,512.90	406,184.95
Other non-recurring expenses		22,109.35	
Total	406,184.95	-79,403.55	406,184.95

(L II) Non-recurring income

A

-

Item	Amount	Amount	Amount
Government grants	12,737.42	154,603.42	12,737.42
Other non-recurring income	12,737.42	154,603.42	12,737.42
Disposal of non-current assets	7,435,774.26	9,470,530.18	7,435,774.26
Government grants	55,075.00	265,600.00	55,075.00
Government grants	60.10		60.10
Provision of non-current assets	35,711.51		35,711.51
Disposal of non-current assets		1,800,000.00	
Government grants	12,000.00		12,000.00
Government grants	15,000.00		15,000.00
Other non-recurring income	987,619.57	145,198.20	987,619.57
Total	8,553,977.86	11,835,931.80	8,553,977.86

Notes to Financial Statements
 F 2022
 (A RMB Y)

V. N ()

(L) N - t (t)

G -

Item	A , t f . h	A	A - /
S W - W 2021		100,000.00	I -
P H D P		150,000.00	I -
S D I S	5,000.00		I -
F C A D R			
M R D	75.00		I -
E T C A	5,000.00		I -
S B L E H	40,000.00		I -
S B L E H	5,000.00		I -
I F P H B		15,600.00	I -
T	55,075.00	265,600.00	

(L) N - t

A

Item	A , t f . h	A	A -
L	1,587,610.46	165,976.73	1,587,610.46
I : F	1,587,610.46	165,976.73	1,587,610.46
E	3,927,631.03	3,333,396.94	3,927,631.03
	521,375.57		521,375.57
L	99,809.90		99,809.90
P	267,628.43		267,628.43
L	1,754,450.54	3,398,511.21	1,754,450.54
O	1,182,532.80	1,738,698.54	1,182,532.80
T	9,341,038.73	8,636,583.42	9,341,038.73

N t t b F		t t t	
F	2022		
(A	RMB Y	)	
V. N		(	)
(LI) I	t		
1. T			
		A , t f b	A
It			
C		40,192,565.61	26,919,820.08
D		-13,618,853.12	

V. N. ()





1. B_{max} $\rightarrow$ B_{min}

It is not clear whether the β values are the same for all the α values. A β value of 0.5 is obtained for $\alpha = 0.5$ and $\alpha = 0.7$ and a β value of 0.4 is obtained for $\alpha = 0.6$. A β value of 0.3 is obtained for $\alpha = 0.4$ and $\alpha = 0.3$. It is not clear whether the β values are the same for all the α values. A β value of 0.5 is obtained for $\alpha = 0.5$ and $\alpha = 0.7$ and a β value of 0.4 is obtained for $\alpha = 0.6$. A β value of 0.3 is obtained for $\alpha = 0.4$ and $\alpha = 0.3$.

	Value	Value
C	-24,220,782.31	44,035,995.21
W	74,600,300.00	72,140,300.00
B	-0.32	0.61
I	-0.32	0.61

2. D

It is not clear whether the β values are the same for all the α values. A β value of 0.5 is obtained for $\alpha = 0.5$ and $\alpha = 0.7$ and a β value of 0.4 is obtained for $\alpha = 0.6$. A β value of 0.3 is obtained for $\alpha = 0.4$ and $\alpha = 0.3$. It is not clear whether the β values are the same for all the α values. A β value of 0.5 is obtained for $\alpha = 0.5$ and $\alpha = 0.7$ and a β value of 0.4 is obtained for $\alpha = 0.6$. A β value of 0.3 is obtained for $\alpha = 0.4$ and $\alpha = 0.3$.

C		-24,220,782.31	44,035,995.21
W		74,600,300.00	74,600,300.00
D		-0.32	0.59
I		-0.32	0.59

N t t h F t t t

F 2022
(A RMB Y)

V. N. ()

(LIII) , t y f t t h t t t f y t

T
 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100. 101. 102. 103. 104. 105. 106. 107. 108. 109. 110. 111. 112. 113. 114. 115. 116. 117. 118. 119. 120. 121. 122. 123. 124. 125. 126. 127. 128. 129. 130. 131. 132. 133. 134. 135. 136. 137. 138. 139. 140. 141. 142. 143. 144. 145. 146. 147. 148. 149. 150. 151. 152. 153. 154. 155. 156. 157. 158. 159. 160. 161. 162. 163. 164. 165. 166. 167. 168. 169. 170. 171. 172. 173. 174. 175. 176. 177. 178. 179. 180. 181. 182. 183. 184. 185. 186. 187. 188. 189. 190. 191. 192. 193. 194. 195. 196. 197. 198. 199. 200. 201. 202. 203. 204. 205. 206. 207. 208. 209. 210. 211. 212. 213. 214. 215. 216. 217. 218. 219. 220. 221. 222. 223. 224. 225. 226. 227. 228. 229. 230. 231. 232. 233. 234. 235. 236. 237. 238. 239. 240. 241. 242. 243. 244. 245. 246. 247. 248. 249. 250. 251. 252. 253. 254. 255. 256. 257. 258. 259. 260. 261. 262. 263. 264. 265. 266. 267. 268. 269. 270. 271. 272. 273. 274. 275. 276. 277. 278. 279. 280. 281. 282. 283. 284. 285. 286. 287. 288. 289. 290. 291. 292. 293. 294. 295. 296. 297. 298. 299. 300. 301. 302. 303. 304. 305. 306. 307. 308. 309. 310. 311. 312. 313. 314. 315. 316. 317. 318. 319. 320. 321. 322. 323. 324. 325. 326. 327. 328. 329. 330. 331. 332. 333. 334. 335. 336. 337. 338. 339. 340. 341. 342. 343. 344. 345. 346. 347. 348. 349. 350. 351. 352. 353. 354. 355. 356. 357. 358. 359. 360. 361. 362. 363. 364. 365. 366. 367. 368. 369. 370. 371. 372. 373. 374. 375. 376. 377. 378. 379. 380. 381. 382. 383. 384. 385. 386. 387. 388. 389. 390. 391. 392. 393. 394. 395. 396. 397. 398. 399. 400. 401. 402. 403. 404. 405. 406. 407. 408. 409. 410. 411. 412. 413. 414. 415. 416. 417. 418. 419. 420. 421. 422. 423. 424. 425. 426. 427. 428. 429. 430. 431. 432. 433. 434. 435. 436. 437. 438. 439. 440. 441. 442. 443. 444. 445. 446. 447. 448. 449. 450. 451. 452. 453. 454. 455. 456. 457. 458. 459. 460. 461. 462. 463. 464. 465. 466. 467. 468. 469. 470. 471. 472. 473. 474. 475. 476. 477. 478. 479. 480. 481. 482. 483. 484. 485. 486. 487. 488. 489. 490. 491. 492. 493. 494. 495. 496. 497. 498. 499. 500. 501. 502. 503. 504. 505. 506. 507. 508. 509. 510. 511. 512. 513. 514. 515. 516. 517. 518. 519. 520. 521. 522. 523. 524. 525. 526. 527. 528. 529. 530. 531. 532. 533. 534. 535. 536. 537. 538. 539. 540. 541. 542. 543. 544. 545. 546. 547. 548. 549. 550. 551. 552. 553. 554. 555. 556. 557. 558. 559. 560. 561. 562. 563. 564. 565. 566. 567. 568. 569. 570. 571. 572. 573. 574. 575. 576. 577. 578. 579. 580. 581. 582. 583. 584. 585. 586. 587. 588. 589. 590. 591. 592. 593. 594. 595. 596. 597. 598. 599. 600. 601. 602. 603. 604. 605. 606. 607. 608. 609. 610. 611. 612. 613. 614. 615. 616. 617. 618. 619. 620. 621. 622. 623. 624. 625. 626. 627. 628. 629. 630. 631. 632. 633. 634. 635. 636. 637. 638. 639. 640. 641. 642. 643. 644. 645. 646. 647. 648. 649. 650. 651. 652. 653. 654. 655. 656. 657. 658. 659. 660. 661. 662. 663. 664. 665. 666. 667. 668. 669. 670. 671. 672. 673. 674. 675. 676. 677. 678. 679. 680. 681. 682. 683. 684. 685. 686. 687. 688. 689. 690. 691. 692. 693. 694. 695. 696. 697. 698. 699. 700. 701. 702. 703. 704. 705. 706. 707. 708. 709. 710. 711. 712. 713. 714. 715. 716. 717. 718. 719. 720. 721. 722. 723. 724. 725. 726. 727. 728. 729. 730. 731. 732. 733. 734. 735. 736. 737. 738. 739. 740. 741. 742. 743. 744. 745. 746. 747. 748. 749. 750. 751. 752. 753. 754. 755. 756. 757. 758. 759. 760. 761. 762. 763. 764. 765. 766. 767. 768. 769. 770. 771. 772. 773. 774. 775. 776. 777. 778. 779. 780. 781. 782. 783. 784. 785. 786. 787. 788. 789. 790. 791. 792. 793. 794. 795. 796. 797. 798. 799. 800. 801. 802. 803. 804. 805. 806. 807. 808. 809. 810. 811. 812. 813. 814. 815. 816. 817. 818. 819. 820. 821. 822. 823. 824. 825. 826. 827. 828. 829. 830. 831. 832. 833. 834. 835. 836. 837. 838. 839. 84

| It | A | A |
|----|------------------|------------------|
| E | 538,910,495.15 | 435,967,572.12 |
| P | 417,971,255.04 | 353,105,992.03 |
| C | | 15,204,373.00 |
| D | 53,029,785.07 | 45,173,131.23 |
| D | 38,189,335.84 | 45,435,380.70 |
| A | 22,991,163.56 | 15,010,629.62 |
| A | 46,397,646.59 | 38,371,918.45 |
| H | 17,904,619.09 | 15,472,884.97 |
| C | 66,553,544.09 | 57,050,465.71 |
| U | 29,928,936.30 | 24,096,157.46 |
| O | 23,086,080.63 | 21,047,712.17 |
| T | 27,657,239.14 | 25,603,836.37 |
| C | 28,302,685.02 | 13,820,361.56 |
| A | 6,366,300.00 | 1,222,900.00 |
| P | 3,526,992.98 | 2,990,339.08 |
| T | 5,332,487.78 | 4,416,545.06 |
| O | 8,492,200.89 | 9,312,807.52 |
| S | 12,214,418.85 | 15,932,752.35 |
| O | 39,035,944.67 | 43,866,151.22 |
| T | 1,385,891,130.69 | 1,183,101,910.62 |

North **East** **South** **West** **Central** **Other**
 F 2022
 (A RMB Y)

V. N ()

(LI) It

1. G

| It | A | A |
|----|----------------|---------------|
| R | 40,253,328.59 | 45,945,728.57 |
| G | 14,633,117.41 | 13,579,087.19 |
| L | 8,067,969.32 | 7,012,773.24 |
| D | 10,116,855.54 | 12,851,693.57 |
| I | 12,751,158.99 | 14,960,534.77 |
| N | 1,035,391.18 | 1,870,927.58 |
| R | 14,000,000.00 | |
| T | 100,857,821.03 | 96,220,744.92 |

2. G

| It | A | A |
|----|----------------|---------------|
| I | 30,632,892.49 | 23,313,110.97 |
| C | 82,155,141.49 | 54,235,967.08 |
| D | 6,608,712.31 | 6,714,560.33 |
| N | 2,927,440.32 | 4,469,403.02 |
| F | 1,082,364.51 | 1,442,594.04 |
| R | 12,498,972.00 | |
| T | 135,905,523.12 | 90,175,635.44 |

3. G

| It | B | B |
|----|--------------|---|
| N | 8,770,704.43 | |
| T | 8,770,704.43 | |

Notes to the Financial Statements
 For the Year Ended December 31, 2022
 (All amounts in RMB Yuan, unless otherwise specified)

V. Non-current Assets

(LI) It is the difference between the total assets and the total liabilities.

4. Goodwill

| Item | Amount at the end of the year | Amount at the beginning of the year |
|----------|-------------------------------|-------------------------------------|
| Goodwill | 150,684,059.10 | |
| Goodwill | 736,190.90 | |
| Total | 151,420,250.00 | |

5. Intangible Assets

| Item | Amount at the end of the year | Amount at the beginning of the year |
|------------|-------------------------------|-------------------------------------|
| Goodwill | 8,096,992.56 | |
| Goodwill | 43,524,302.81 | 44,807,765.61 |
| Fair value | 4,500,000.00 | 750,000.00 |
| Goodwill | - | 15,118,800.00 |
| Total | 56,121,295.37 | 60,676,565.61 |

2022 (A 2022 RMB Y)

V. N ()

(L) , t y f t t b h f t t t

1. S 2022 12 31

| | A t f b | A |
|---------|-----------------|----------------|
| t y f t | t | |
| 1. R | | |
| N | -10,968,838.36 | 40,860,230.05 |
| A : C | 25,191,541.19 | 2,140,196.45 |
| P | 10,345,460.56 | 6,179,290.37 |
| D | 53,029,785.07 | 48,274,868.81 |
| C | | |
| D | 38,189,335.84 | 41,779,572.06 |
| A | 22,991,163.56 | 14,530,192.10 |
| A | 46,397,646.59 | 38,836,785.71 |
| L | | |
| () | -406,184.95 | 79,403.55 |
| L | 1,574,873.04 | 11,373.31 |
| L | 15,977,325.91 | -9,417,390.73 |
| F | 45,071,535.43 | 36,306,461.06 |
| I | -2,850,458.27 | -6,937,845.27 |
| D | -6,345,432.93 | 27,745,384.58 |
| I | 672,088.86 | 14,843,351.28 |
| D | -1,812,096.14 | -19,010,829.84 |
| D | -137,055,559.27 | -37,743,452.80 |
| I | 127,218,378.32 | -4,581,092.21 |
| O | | |
| N | 227,220,564.45 | 193,896,498.48 |
| 2. S | | |
| C | | |
| C | | |
| F | | |
| 3. N | | |
| G | 258,595,990.97 | 188,734,845.77 |
| L : G | 188,734,845.77 | 200,092,665.42 |
| A : G | | |
| L : G | | |
| N | 69,861,145.20 | -11,357,819.65 |

Notes to Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

V. Notes to Financial Statements (Continued)

(L) ... (R) ...

2. Notes to Financial Statements (Continued)

Amount

| | |
|---------------------------------------|---------------|
| General ... | 54,309,855.16 |
| I ... : J ... S ... H ... C., L. ... | 21,684,900.00 |
| Y ... Y ... TCM- ... H ... C., L. ... | 32,624,955.16 |
| L ... : C ... | 624,153.88 |
| I ... : J ... S ... H ... C., L. ... | 624,153.88 |
| Y ... Y ... TCM- ... H ... C., L. ... | |
| A ... : C ... | |
| O ... | 53,685,701.28 |

3. Notes to Financial Statements (Continued)

| Item | Amount | Amount |
|------------------|----------------|----------------|
| I. General ... | 258,595,990.97 | 188,734,845.77 |
| I ... : C ... | 454,907.26 | 971,773.72 |
| D ... | | |
| C ... | 257,534,338.59 | 187,484,938.31 |
| O ... | 606,745.12 | 278,133.74 |
| D ... | | |
| D ... | | |
| L ... | | |
| II. General ... | | |
| I ... : B ... | | |
| III. General ... | 258,595,990.97 | 188,734,845.77 |
| I ... : U ... | | |
| G ... | | |

Notes to the Financial Statements
F 2022
(A RMB Y)

V. N ()

(L I) A h t t h t-f

C y t

| It | f h | R |
|----|----------------|---|
| M | 498,972.00 | B |
| | 12,000,000.00 | P |
| F | 35,612,151.67 | C |
| | 73,406,248.95 | S |
| I | 6,107,838.02 | C |
| T | 133,942,408.61 | |

(L II) G t t

P N V (XLIII) N V (XLIX)

VI. C

(I) B t t t

1. B

f C t f P t f
t f t f t t
N f t t t t (%)

2022 年 12 月 31 日止
 2022 年 12 月 31 日止
 (A 股) (人民币元)

VI. C 类 ()

(I) B 类 ()

2. C 类

Y Y J Y S Z F

Notes to the Financial Statements
F 2022
(A RMB Y)

VI. C ()

(I) B ()

2. C (C)

(2) I J 2022, Z K H M (G) C L ()
Z K), C C J Y
X , Z F N T C , L . ()
Z F), S ' A Z F
N T C , L , C RMB3,000,000.00
RMB2,673,987.56 Z
F , RMB326,012.44.

3. I ()

| | Y | Y | J S | Z F | | |
|-----|---------------|---------------|---------------|---------------|--------------|--------------|
| | Fe | Ge | Fe | Ge | | |
| | | | | | | |
| A : | 59,544,389.38 | 46,544,389.38 | 37,912,065.31 | 21,595,600.11 | 3,596,967.56 | 3,596,967.56 |
| C | | | 624,153.88 | 624,153.88 | 3,003,084.38 | 3,003,084.38 |
| R | 3,060,406.64 | 3,060,406.64 | 7,552,399.46 | 7,552,399.46 | | |
| I | | | 505,619.01 | 504,706.60 | 590,783.18 | 590,783.18 |
| O | | | 22,965.97 | 22,965.97 | | |
| F | 4,043,853.80 | 4,043,853.80 | 847,808.30 | 394,720.51 | 3,100.00 | 3,100.00 |
| C | | | 6,651,653.69 | 6,651,653.69 | | |
| I | 13,299,835.09 | 299,835.09 | 15,862,465.00 | | | |
| L - | 24,864,697.08 | 24,864,697.08 | | | | |
| O - | 14,275,596.77 | 14,275,596.77 | 5,845,000.00 | 5,845,000.00 | | |
| L : | 17,960,741.79 | 17,960,741.79 | 8,244,110.73 | 4,164,994.43 | 422,980.00 | 422,980.00 |
| B | | | | | | |
| P | 14,710,741.79 | 14,710,741.79 | 4,099,565.00 | 4,099,565.00 | 261,041.74 | 261,041.74 |
| E | | | 618,827.28 | 618,827.28 | 159,133.43 | 159,133.43 |
| T | | | -553,397.85 | -553,397.85 | 2,804.83 | 2,804.83 |
| D | 3,250,000.00 | 3,250,000.00 | 4,079,116.30 | | | |
| N | 41,583,647.59 | 28,583,647.59 | 29,667,954.58 | 17,430,605.68 | 3,173,987.56 | 3,173,987.56 |
| L : | | | 15,130,745.84 | 8,889,661.19 | 500,000.00 | 500,000.00 |
| N | 41,583,647.59 | 28,583,647.59 | 14,537,208.74 | 8,540,944.49 | 2,673,987.56 | 2,673,987.56 |

M : T C

Net Profit attributable to the Company's shareholders in 2022
(Attributable to the Company's shareholders) (RMB Y)

VI. Cash and cash equivalents (RMB Y)

(III) Cash and cash equivalents at the end of the reporting period

T 2022 12 31 2021 12 31 Z H H RMB7.23 . A
, C 47.48% Z H H

Notes to Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

VII.1

(I) Investment in subsidiaries

1. Subsidiaries

| | | Percentage of ownership (%) | |
|-------------------------------------|--------------------|-----------------------------|-------------------------|
| Subsidiary Name | Registered Capital | Percentage of ownership | Percentage of ownership |
| Wenzhou Kangning Hospital Co., Ltd. | 100,000,000.00 | 100.00 | 100.00 |

Notes to Financial Statements
F 2022
(A RMB Y)

VII.I ()

(I) I t t (t)

1. S G ()

| Name of the company | Type of investment | Percentage of investment | Nature of investment | Investment amount (0000'Y) | Percentage of investment (%) | | |
|---------------------|--------------------|--------------------------|----------------------|-----------------------------|------------------------------|----------|----------------------|
| | | | | | Direct | Indirect | Method of investment |
| Z Y H T Y LLC | H | H | T Y | 2,040.82 | 98.00 | I | |
| C.,L. | | | | | | | |
| W Y D C.,L. | W | W | D | 50 | 100.00 | I | |
| Y M H E-H | W | W | H | 500 | 100.00 | I | |
| (W)C.,L. | | | | | | | |
| Z D P | W | W | P | 1,000 | 80.00 | I | |
| C.,L. | | | | | | | |
| C K P | C | C | M | 2,700 | 64.55 | B | |
| H C.,L. | | | | | | | |
| C Q L K | H | H | M | 1,000 | 100.00 | I | |
| H C.,L. | | | | | | | |
| H Y M E | H | H | T Y | 500 | 100.00 | I | |
| R&DC.,L. | | | | | | | |
| H Y N S | H | H | N | 100 | 100.00 | I | |
| C.,L. | | | | | | | |
| L C H C.,L. | T | T | M | 5,000 | 100.00 | I | |
| S Y H | S | S | M | 6,000 | 55.00 | I | |
| P Y H H | J | J | M | 1,660 | 100.00 | I | |
| C.,L. | | | | | | | |
| (浦江怡寧黃鋒醫院有限公司) | | | | | | | |
| C K H | H | H | M | 1,000 | 100.00 | I | |
| H C.,L. | | | | | | | |
| C K H C.,L. | C | C | M | 5,000 | 100.00 | I | |
| C Y N C | C | C | M | 1,000 | 100.00 | I | |
| C.,L. | | | | | | | |
| Y K H C.,L. | Y | Y | M | 100 | 100.00 | I | |
| L K H C.,L. | T | T | M | 200 | 80.00 | I | |
| O Y E YH C.,L. | W | W | M | 1,000 | 100.00 | I | |
| Q K H C.,L. | L | L | M | 3,200 | 100.00 | I | |
| S Y M I | S | S | M | 1,000 | 100.00 | I | |
| C.,L. | | | | | | | |

Notes to Financial Statements
F 2022
(A RMB Y)

| | | | | | Ownership (%) | | |
|---|------------|--------------------------|---------------------|---------------------|---------------|--------|-------------------------------------|
| Investor | Investment | Proportion of Investment | Proportion of Share | Proportion of Share | (0000Y) | Direct | Indirect |
| Wenzhou Kangning Hospital Co., Ltd. LLC | W | W | M | 2,585.98 | 100.00 | B | |
| | | | | | | | Wenzhou Kangning Hospital Co., Ltd. |

(

(

(

[illegible]

(

t

t

2022
RMB Y

Notes to Financial Statements
F 2022
(A RMB Y)

VIII. R

D , C : ,
(,). T
C :

T C ,
C . T C
C . T
, . T C
C
. T C S R M C
. T S R M C
,
C T C A C .

T C
 ,
 .

(I) C

C C

T C , , , .

T C -
 - . T C
 .

Notes to the Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan unless otherwise specified)

VIII. Revenue

(I) Contract revenue (continued)

For the year ended December 31, 2022, the Company's revenue is derived from the sale of medical services, medical materials, medical equipment, and medical information services. The revenue is recognized when the Company has transferred the control of the goods or services to the customer, and the amount of revenue is determined based on the contract price. The revenue is classified into medical services revenue, medical materials revenue, medical equipment revenue, and medical information services revenue. The revenue is recognized when the Company has transferred the control of the goods or services to the customer, and the amount of revenue is determined based on the contract price. The revenue is classified into medical services revenue, medical materials revenue, medical equipment revenue, and medical information services revenue.

(II) Leasing revenue

For the year ended December 31, 2022, the Company's leasing revenue is derived from the leasing of medical equipment. The revenue is recognized when the Company has transferred the control of the goods or services to the customer, and the amount of revenue is determined based on the contract price. The revenue is classified into medical equipment leasing revenue. The revenue is recognized when the Company has transferred the control of the goods or services to the customer, and the amount of revenue is determined based on the contract price. The revenue is classified into medical equipment leasing revenue.

For the year ended December 31, 2022, the Company's revenue is derived from the sale of medical services, medical materials, medical equipment, and medical information services. The revenue is recognized when the Company has transferred the control of the goods or services to the customer, and the amount of revenue is determined based on the contract price. The revenue is classified into medical services revenue, medical materials revenue, medical equipment revenue, and medical information services revenue.

Contract revenue

| Item | Contract revenue | 1-12 months | 1-2 years | 2-5 years | Over 5 years | Total |
|-------------------|------------------|----------------|----------------|---------------|----------------|------------|
| Medical services | 997,944.00 | | | | | 997,944.00 |
| Medical materials | 211,396,818.18 | 223,154,176.00 | 153,052,040.00 | 69,285,680.00 | 656,888,714.18 | |
| Medical equipment | 99,580,000.00 | 28,954,752.75 | 26,076,534.51 | | 154,611,287.26 | |
| Total | 311,974,762.18 | 252,108,928.75 | 179,128,574.51 | 69,285,680.00 | 812,497,945.44 | |

Notes to the Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

VIII. Revenue ()

(II) Operating Revenue ()

| I | By type of service | | | | Total |
|--------------------------------------|--------------------|---------------------|-------------------|--------|----------------|
| | Medical | Medical examination | Medical treatment | Others | |
| | | 1 | 1-2 | 2-5 | |
| Balance at the beginning of the year | | 254,050,000.00 | | | 254,050,000.00 |

Notes to the Financial Statements
F 2022
(A RMB Y)

VIII. R ()

(III) M ()

Notes to Financial Statements
F 2022
(A RMB Y)

VIII. R ()

(III) M ()

3) O

O
T C
O 31 D 2022, RMB1,893,506
RMB1,893,506, 3%, 3%

IX. D

T
L 1
L 2
L 3
T

IX. D

(I) $C \xrightarrow{f} f^*t \xrightarrow{t} t^f$

| It. | Cassa di Roma | | | | | |
|-------|---------------|------------|---------------|--------|--|---------------|
| | M...tL...1 | M...tL...2 | M...tL...3 | Totale | | |
| I. C | | | | | | |
| F | | | 10,641,026.00 | | | 10,641,026.00 |
| 1. F | | | 10,641,026.00 | | | 10,641,026.00 |
| (1) | | | | | | |
| (2) I | | | 10,641,026.00 | | | 10,641,026.00 |
| (3) | | | | | | |
| 2. F | | | | | | |
| T | | | 10,641,026.00 | | | 10,641,026.00 |
| | | | 13,922,929.38 | | | 13,922,929.38 |
| 1. | | | 13,922,929.38 | | | 13,922,929.38 |
| (1) | | | | | | |
| (2) | | | | | | |
| (3) | | | 13,922,929.38 | | | 13,922,929.38 |
| 2. F | | | | | | |
| | | | | | | |
| T | | | 13,922,929.38 | | | 13,922,929.38 |

[illegible]

- [illegible]

Ninth Edition

F 2022
(A RMB Y)

X. R

() If t f b t y

T. C. : G. W. , W. L. .

(.) If $t \in \mathcal{C}$ and $y \in \mathcal{C}$,

D ♣ C ♣ ♠ ♠ N VII. I .

() If $t \in C$ then $t \in C$

F  C     ,  N VII. I

•

T

C

:

N f t t t t t h b b C y

C H $\rightarrow$ K H $\rightarrow$ C, L.

A C

W A P C ., L

A C

C Y H C., L .

A C

H. Y. H. C., L.

A C

Notes to Financial Statements
F 2022
(A RMB Y)

X. R ()

(I) If the following items are:

| Notes to Financial Statements | Notes to Financial Statements | Notes to Financial Statements |
|-------------------------------|-------------------------------|-------------------------------|
| Y M H C | N - | C |
| N M B P A K | P | C |
| I M P | | |
| (L L P) | | |
| N F T Z S | | |
| I T C., L | | |
| S F H M | N - | C |
| C., L | | |
| W L | N - | C |
| Q K | N - | C |
| W H | D, , | |
| Z T E C | N - | C |
| C., L | | |

() If the following items are:

| 1. R | | | |
|-------------------------------|---|--------------|--------------|
| S | / | | |
| Notes to Financial Statements | C | A, t f | A |
| Y M H C | M | 3,000,000.00 | 3,000,000.00 |
| C H K H C., L | | 71,199.48 | |
| W A P C., L | | 54,281.47 | 456,272.70 |
| J S H C., L | | | 2,372,524.98 |
| R | | | 682,184.79 |

Notes to Financial Statements
For the year ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

X. Related Party Transactions (Continued)

() If the transaction is not a financial transaction, it should be marked with a checkmark ()

3. Related Party Transactions

Transaction Description:

| Transaction Description | Contract Amount (RMB) | Contract Date | Contract Expiry Date | Contract Status |
|-------------------------|-----------------------|---------------|----------------------|-----------------|
| Y. K. H. C., Ltd. | 50,200,000.00 | 2019/8/26 | 2029/8/20 | N |
| Q. K. H. C., Ltd. | 45,000,000.00 | 2019/12/31 | 2024/12/31 | N |

Transaction Description:

| Transaction Description | Contract Amount (RMB) | Contract Date | Contract Expiry Date | Contract Status |
|-------------------------|-----------------------|---------------|----------------------|-----------------|
| G. W. W. L. Y. | 30,000,000.00 | 2020/6/30 | 2027/6/30 | N |
| G. W. W. H. Y. | 75,000,000.00 | 2021/11/29 | 2028/11/29 | N |
| G. W. W. H. Y. W. L. Y. | 150,000,000.00 | 2020/10/26 | 2026/10/25 | N |
| G. W. W. L. Y. W. H. Y. | 200,000,000.00 | 2020/9/17 | 2023/9/17 | N |

4. Assets Held for Sale

Contract Amount (RMB) Contract Date Contract Expiry Date

Notes to the Financial Statements
F 2022
(A RMB Y)
X. R ()

Notes to the Financial Statements
For the Year Ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

X. Receivables ()

(II) Earnings before income tax

In 2022, the company's earnings before income tax were RMB 2,391,424.85.

| Name | Current year | | Previous year | | Other | |
|----------------------------|--------------------------------------|------------------------|--------------------------------------|------------------------|--------------------------------------|------------------------|
| | Balance at the beginning of the year | Change during the year | Balance at the beginning of the year | Change during the year | Balance at the beginning of the year | Change during the year |
| Earnings before income tax | | | | | | |
| Government grants | | 413,976.00 | | 70,950.72 | 79,754.00 | 2,000.00 |
| Warranty income | | 516,000.00 | | | 96,000.00 | 71,000.00 |
| Warranty income | | 231,450.00 | | 50,888.16 | | 600.00 |
| Net income | | | | | | |
| Qinghai | | | | | | |
| Licenses | | | | | | |
| Income tax | | | | | | |
| Zhang X | 70,000.00 | | | | | 70,000.00 |
| Zhang W | 70,000.00 | | | | | 70,000.00 |
| Liu N | 70,000.00 | | | | | 70,000.00 |
| Income tax | | | | | | |
| Qinghai | | | | | | |
| Xin Y | | | | | | |
| Sun F | | | | | | |
| Xin N | | 313,320.00 | | 56,939.80 | 36,000.00 | 32,200.00 |
| Xin T | | 98,760.00 | | 40,146.72 | 67,954.00 | 3,485.45 |
| Total | 210,000.00 | 1,573,506.00 | 218,925.40 | 279,708.00 | 109,285.45 | 2,391,424.85 |

Other:

On September 1, 2022, Wang H, Zhang W, and Liu N, who are the company's directors, resigned from their positions as directors. On September 19, 2022, Sun F, who is the company's director, resigned from his position as director.

2022 年 12 月 31 日止年度财务报表附注

F 附注 2022
 (A 附注 RMB Y 附注)

X. R 附注 附注 附注 附注 附注 附注 附注 (附注)

(II)E 附注 附注 附注 附注 (C 附注 附注)

I 2021, 附注 , 附注 附注 附注 :

C

| 附注 | E | 附注 | 附注 | B | O | 附注 | T 附注 |
|---------------|------------|--------------|-----------|------------|-----------|----|--------------|
| 附注 附注 附注 | | | | | | | |
| G 附注 W | - | 398,742.00 | 15,795.90 | 78,916.40 | 4,300.00 | | 497,754.30 |
| W 附注 L 附注 附注 | - | 375,592.00 | - | 46,714.60 | 44,680.00 | | 466,986.60 |
| W 附注 H 附注 附注 | - | 208,108.00 | - | 42,396.60 | 1,200.00 | | 251,704.60 |
| 附注 附注 附注 附注 | | | | | | | |
| L L | - | - | - | - | - | - | - |
| Y 附注 Y 附注 | - | 28,200.00 | 4,986.80 | 32,385.97 | 8,932.90 | | 74,505.67 |
| I 附注 附注 附注 附注 | | | | | | | |
| Z 附注 X | 70,000.00 | - | - | - | - | - | 70,000.00 |
| Z W 附注 | 70,000.00 | - | - | - | - | - | 70,000.00 |
| L N | 70,000.00 | - | - | - | - | - | 70,000.00 |
| 附注 附注 附注 | | | | | | | |
| H 附注 J 附注 | - | - | - | - | - | - | - |
| Q 附注 C 附注 | - | - | - | - | - | - | - |
| C J 附注 | - | - | - | - | - | - | - |
| S 附注 | - | - | - | - | - | - | - |
| X T 附注 | - | 82,613.40 | 8,885.40 | 54,030.60 | 18,936.60 | | 164,466.00 |
| T 附注 | 210,000.00 | 1,093,255.40 | 29,668.10 | 254,444.17 | 78,049.50 | | 1,665,417.17 |

Notes to the Financial Statements

For the year ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

X. Receivables ()

(III) Financial Instruments Held

I 2022, the Company's financial instruments held are as follows:

| Item | Amount at the end of the year | Amount at the beginning of the year |
|--|-----------------------------------|-------------------------------------|
| Whereof: Government bonds, corporate bonds, etc. | 3,764,039.10 | 3,424,382.50 |
| Short-term investments | 4,109,519.26 | 4,411,564.18 |
| Total | 7,873,558.36 | 7,835,946.68 |
| | Number of shares | Number of shares |
| | Weighted average number of shares | Weighted average number of shares |
| 500,000-1,000,000.00 | 1 | 1 |
| Over 1,000,000.00 | 4 | 4 |
| Total | 5 | 5 |

F 2022
(A RMB Y)

XI. S $\frac{1}{2}$ - $\frac{1}{2}$ $\frac{1}{2}$

(I) $\gamma f h - \gamma t$

T C :

O J 13, 2018, C 2018 W
K H E P 2018, B C
T B C P G R
S I O J 29, 2018 A 20, 2018, T C
W Z K I
M (L L P), W J K I M
P (L L P), W E K I M P
(L L P), W J K I M P (L
L P) W S K I M P (L
L P), 2,460,000

Notes to the Financial Statements

F 2022
(A RMB Y)

XI. S - ()

(II) E , ty- tt h - y t

M :
: 2022

T C :
: T :
C RMB30 .

M :
:

Notes to the Financial Statements
F
(A 2022
(A RMB Y)

XII.C C

(I) f t t t

1. C 2 3 4

Notes to the Financial Statements
For the year ended December 31, 2022
(All amounts in RMB Yuan, unless otherwise specified)

XIV. Government Grants

The Company has received government grants for the year ended December 31, 2022, which are classified as follows:

- Government grants related to the Company's research and development activities, which are recognized as income over the period in which the related costs are incurred.

- Government grants related to the Company's operations, which are recognized as income when the Company meets the conditions for receiving the grants.

The Company has received government grants for the year ended December 31, 2022, which are classified as follows:

- Government grants related to the Company's research and development activities, which are recognized as income over the period in which the related costs are incurred.

- Government grants related to the Company's operations, which are recognized as income when the Company meets the conditions for receiving the grants.

The Company has received government grants for the year ended December 31, 2022, which are classified as follows:

- Government grants related to the Company's research and development activities, which are recognized as income over the period in which the related costs are incurred.

- Government grants related to the Company's operations, which are recognized as income when the Company meets the conditions for receiving the grants.

| D | / | B | B |
|--------|---|--------|---|
| | | | |
| 49.73% | | 46.16% | |

N t t h F t t t

F 2022
(A RMB Y)

XV. O

(I) $C \vdash t \neq f$ $\vdash$ $t \neq f$

 R ∇ $\clubsuit$

A 38 M T S B D E M T
S S C C D P R C P
A E ,
2021 :

| C | P | P | Aff | t | t | b | f | C | t |
|---|---|---|-----|---|---|---|---|---------------|---|
| | | | | | | | | | |
| I | B | R | O | | | | | -9,203,741.45 | |
| | | | I | | | | | 12,877.91 | |
| | | | U | | | | | 9,190,863.54 | |

$$(II) \quad t \mid f \quad t$$

A C W G I J 2021, C

(III) Ob f t , h h f , h f t

1. I $\rightarrow$ $\frac{1}{2}I$ $\rightarrow$ $\frac{1}{4}I$ $\rightarrow$ $\frac{1}{8}I$ $\rightarrow$ $\frac{1}{16}I$ $\rightarrow$ $\frac{1}{32}I$ $\rightarrow$ $\frac{1}{64}I$ $\rightarrow$ $\frac{1}{128}I$ $\rightarrow$ $\frac{1}{256}I$ $\rightarrow$ $\frac{1}{512}I$ $\rightarrow$ $\frac{1}{1024}I$ $\rightarrow$ $\frac{1}{2048}I$ $\rightarrow$ $\frac{1}{4096}I$ $\rightarrow$ $\frac{1}{8192}I$ $\rightarrow$ $\frac{1}{16384}I$ $\rightarrow$ $\frac{1}{32768}I$ $\rightarrow$ $\frac{1}{65536}I$ $\rightarrow$ $\frac{1}{131072}I$ $\rightarrow$ $\frac{1}{262144}I$ $\rightarrow$ $\frac{1}{524288}I$ $\rightarrow$ $\frac{1}{1048576}I$ $\rightarrow$ $\frac{1}{2097152}I$ $\rightarrow$ $\frac{1}{4194304}I$ $\rightarrow$ $\frac{1}{8388608}I$ $\rightarrow$ $\frac{1}{16777216}I$ $\rightarrow$ $\frac{1}{33554432}I$ $\rightarrow$ $\frac{1}{67108864}I$ $\rightarrow$ $\frac{1}{134217728}I$ $\rightarrow$ $\frac{1}{268435456}I$ $\rightarrow$ $\frac{1}{536870912}I$ $\rightarrow$ $\frac{1}{1073741824}I$ $\rightarrow$ $\frac{1}{2147483648}I$ $\rightarrow$ $\frac{1}{4294967296}I$ $\rightarrow$ $\frac{1}{8589934592}I$ $\rightarrow$ $\frac{1}{17179869184}I$ $\rightarrow$ $\frac{1}{34359738368}I$ $\rightarrow$ $\frac{1}{68719476736}I$ $\rightarrow$ $\frac{1}{137438953472}I$ $\rightarrow$ $\frac{1}{274877906944}I$ $\rightarrow$ $\frac{1}{549755813888}I$ $\rightarrow$ $\frac{1}{1099511627776}I$ $\rightarrow$ $\frac{1}{2199023255552}I$ $\rightarrow$ $\frac{1}{4398046511104}I$ $\rightarrow$ $\frac{1}{8796093022208}I$ $\rightarrow$ $\frac{1}{17592186044416}I$ $\rightarrow$ $\frac{1}{35184372088832}I$ $\rightarrow$ $\frac{1}{70368744177664}I$ $\rightarrow$ $\frac{1}{140737488355328}I$ $\rightarrow$ $\frac{1}{281474976710656}I$ $\rightarrow$ $\frac{1}{562949953421312}I$ $\rightarrow$ $\frac{1}{1125899906842624}I$ $\rightarrow$ $\frac{1}{2251799813685248}I$ $\rightarrow$ $\frac{1}{4503599627370496}I$ $\rightarrow$ $\frac{1}{9007199254740992}I$ $\rightarrow$ $\frac{1}{18014398509481984}I$ $\rightarrow$ $\frac{1}{36028797018963968}I$ $\rightarrow$ $\frac{1}{72057594037927936}I$ $\rightarrow$ $\frac{1}{144115188075855872}I$ $\rightarrow$ $\frac{1}{288230376151711744}I$ $\rightarrow$ $\frac{1}{576460752303423488}I$ $\rightarrow$ $\frac{1}{1152921504606846976}I$ $\rightarrow$ $\frac{1}{2305843009213693952}I$ $\rightarrow$ $\frac{1}{4611686018427387904}I$ $\rightarrow$ $\frac{1}{9223372036854775808}I$ $\rightarrow$ $\frac{1}{18446744073709551616}I$ $\rightarrow$ $\frac{1}{36893488147419103232}I$ $\rightarrow$ $\frac{1}{73786976294838206464}I$ $\rightarrow$ $\frac{1}{147573952589676412928}I$ $\rightarrow$ $\frac{1}{295147905179352825856}I$ $\rightarrow$ $\frac{1}{590295810358705651712}I$ $\rightarrow$ $\frac{1}{1180591620717411303424}I$ $\rightarrow$ $\frac{1}{2361183241434822606848}I$ $\rightarrow$ $\frac{1}{4722366482869645213696}I$ $\rightarrow$ $\frac{1}{9444732965739290427392}I$ $\rightarrow$ $\frac{1}{18889465931478580854784}I$ $\rightarrow$ $\frac{1}{37778931862957161709568}I$ $\rightarrow$ $\frac{1}{75557863725914323419136}I$ $\rightarrow$ $\frac{1}{151115727451828646838272}I$ $\rightarrow$ $\frac{1}{302231454903657293676544}I$ $\rightarrow$ $\frac{1}{604462909807314587353088}I$ $\rightarrow$ $\frac{1}{1208925819614629174706176}I$ $\rightarrow$ $\frac{1}{2417851639229258349412352}I$ $\rightarrow$ $\frac{1}{4835703278458516698824704}I$ $\rightarrow$ $\frac{1}{9671406556917033397649408}I$ $\rightarrow$ $\frac{1}{19342813113834066795298816}I$ $\rightarrow$ $\frac{1}{38685626227668133590597632}I$ $\rightarrow$ $\frac{1}{77371252455336267181195264}I$ $\rightarrow$ $\frac{1}{154742504910672534362390528}I$ $\rightarrow$ $\frac{1}{309485009821345068724781056}I$ $\rightarrow$ $\frac{1}{618970019642690137449562112}I$ $\rightarrow$ $\frac{1}{1237940039285380274899124224}I$ $\rightarrow$ $\frac{1}{2475880078570760549798248448}I$ $\rightarrow$ $\frac{1}{4951760157141521099596496896}I$ $\rightarrow$ $\frac{1}{9903520314283042199192993792}I$ $\rightarrow$ $\frac{1}{19807040628566084398385987584}I$ $\rightarrow$ $\frac{1}{39614081257132168796771975168}I$ $\rightarrow$ $\frac{1}{79228162514264337593543950336}I$ $\rightarrow$ $\frac{1}{158456325028528675187087900672}I$ $\rightarrow$ $\frac{1}{316912650057057350374175801344}I$ $\rightarrow$ $\frac{1}{633825300114114700748351602688}I$ $\rightarrow$ $\frac{1}{1267650600228229401496703205376}I$ $\rightarrow$ $\frac{1}{2535301200456458802993406410752}I$ $\rightarrow$ $\frac{1}{5070602400912917605986812821504}I$ $\rightarrow$ $\frac{1}{10141204801825835211973625643008}I$ $\rightarrow$ $\frac{1}{20282409603651670423947251286016}I$ $\rightarrow$ $\frac{1}{40564819207303340847894502572032}I$ $\rightarrow$ $\frac{1}{81129638414606681695789005144064}I$ $\rightarrow$ $\frac{1}{162259276829213363391578010288128}I$ $\rightarrow$ $\frac{1}{324518553658426726783156020576256}I$ $\rightarrow$ $\frac{1}{649037107316853453566312041152512}I$ $\rightarrow$ $\frac{1}{1298074214633706907132624082305024}I$ $\rightarrow$ $\frac{1}{2596148429267413814265248164610048}I$ $\rightarrow$ $\frac{1}{5192296858534827628530496329220096}I$

O A 14, 2023, 38 B D W K

H C „ L „

Notes to the Financial Statements

F 2022
(A RMB Y)

XV. O ()

(III) Ob f t , h h f , b f t (t ,)

1. I V ()

(1) I RMB14.43

B S 2022, I
I A ,
2019 2020 RMB14.43 , RMB5.25
RMB9.18 , T
K H ,
I I C B D ,
(I) 2021, N XV

(2) R S W D C

A ,
RMB2,190,700, C
C
T C
C
C

Net Profit 2022

(A RMB Y)

XV. Other ()

(III) Other ()

1. I ()

(3) R

Base S 2022, :
:

Part I : I C C
C , C
C A
C C
C

A : B C C
C C
C , C
C C T
C

Notes to the Financial Statements

F 2022
(A RMB Y)

XV. Other Non-current Assets

(III) Other Non-current Assets

2. A ()

(2) I 12 2019, 2020 2021
2020 2021
C
2020 2021, T
RMB428,900 2020 RMB335,100 2021,
C
2020 2021.

(3) O , C 2022

XVI. Non-current Assets Held for Sale

(I) A

1. A

| A | B | B |
|-----|---------------|---------------|
| | t | a a |
| | f | |
| W 1 | 49,024,983.98 | 40,904,137.67 |
| 1-2 | 709,878.26 | 1,282,268.26 |
| 2-3 | 1,158,221.95 | 2,748,299.92 |
| O 3 | 2,748,299.92 | 1,204,242.08 |
| S | Over 3 years | 1,158,221.95 |

Non-current Financial Assets
F
(A 2022
RMB Y)

| C t y | A t t | | B t t | | P t t | | B t t | | P t t | | B t t | |
|-------|-------|---------------|--------|---------------|--------|---------------|--------|---------------|--------|---------------|-------|---------------|
| | (%) | A t t | (%) | B t t | (%) | P t t | (%) | A t t | (%) | P t t | (%) | B t t |
| A | | 4,873,715.26 | 9.09 | 4,873,715.26 | 100.00 | | | 5,315,384.45 | 11.52 | 2,657,692.22 | 50.00 | 2,657,692.22 |
| I : | | | | | | | | | | | | |
| M | | 4,873,715.26 | 9.09 | 4,873,715.26 | 100.00 | | | 5,315,384.45 | 11.52 | 2,657,692.22 | 50.00 | 2,657,692.22 |
| A | | 48,767,668.85 | 90.91 | 48,767,668.85 | 1.00 | 48,279,992.16 | 88.48 | 40,823,563.48 | 88.48 | 40,415,327.85 | 1.00 | 40,415,327.85 |
| I : | | | | | | | | | | | | |
| O | | 48,767,668.85 | 90.91 | 48,767,668.85 | 1.00 | 48,279,992.16 | 88.48 | 40,823,563.48 | 88.48 | 40,415,327.85 | 1.00 | 40,415,327.85 |
| T | | 53,641,384.11 | 100.00 | 5,361,391.95 | | 48,279,992.16 | 100.00 | 46,138,947.93 | 100.00 | 3,065,927.86 | | 43,073,020.07 |
| A | | | | | | | | | | | | |
| It | | | | | | | | | | | | |
| M | | 4,873,715.26 | | 4,873,715.26 | | 4,873,715.26 | 100.00 | | | | | |
| T | | 4,873,715.26 | | 4,873,715.26 | | 4,873,715.26 | | | | | | |

Notes to the Financial Statements
F
(A 2022
(A RMB Y)

XVI. N ()

(I) A ()

2. A ()
A :

| Item | B () | | |
|-------|---------------|------------|-------|
| | A () | P () | P () |
| Other | 48,767,668.85 | 487,676.69 | 1.00 |
| Total | 48,767,668.85 | 487,676.69 | |

3. P ()
B ()

C ()

Notes to the Financial Statements
F 2022
(A RMB Y)

XVI. N ()

(II) Ob

| Item | Balance at the beginning of the period | Balance at the end of the period |
|--------------|--|----------------------------------|
| I | | |
| D | 53,000,000.00 | |
| O | 547,014,558.58 | 492,034,884.26 |
| T | 600,014,558.58 | 492,034,884.26 |
| 1. D | | |
| | Balance at the beginning of the period | Balance at the end of the period |
| | | |
| G K H C., L. | 33,000,000.00 | |
| Y K H C., L. | 10,000,000.00 | |
| Q K H C., L. | 10,000,000.00 | |
| S | 53,000,000.00 | |
| L : P | | |

North East
F 2022
(A RMB Y)

(

)

(II) Ob (t r)

XVI, N

Notes to the Financial Statements
F 2022
(A RMB Y)

XVI. N ()

(II) Ob ()

(3) P V

| P f t | t 1
12- h
ECL | t 2
L f t ECL
(N t
(t)) | t 3
L f t ECL
(C t-
(t)) | t |
|---------|---------------------|----------------------------------|-----------------------------------|------------|
| | | | | |
| B h h | 123,061.04 | | | 123,061.04 |
| B h h | | | | |
| h / | | | | |
| - T h 2 | | | | |
| - T h 3 | | | | |
| - R h 2 | | | | |
| - R h 1 | | | | |
| P h | 103,420.62 | | | 103,420.62 |
| R h | | | | |
| W h | | | | |
| W | | | | |
| O h | | | | |
| B h h | 226,481.66 | | | 226,481.66 |

C h h h h :

| B | t 1
12- h
ECL | t 2
L f t ECL
(N t
(t)) | t 3
L f t ECL
(C t-
(t)) | t |
|---------|---------------------|----------------------------------|-----------------------------------|----------------|
| | | | | |
| B h h | 492,157,945.30 | | | 492,157,945.30 |
| B h h | | | | |
| h / | | | | |
| - T h 2 | | | | |
| - T h 3 | | | | |
| - R h 2 | | | | |
| - R h 1 | | | | |
| A | 55,083,094.94 | | | 55,083,094.94 |
| D | | | | |
| O h | | | | |
| B h h | 547,241,040.24 | | | 547,241,040.24 |

Notes to Financial Statements
 For the year ended December 31, 2022
 (All amounts in RMB Yuan, unless otherwise specified)

XVI. Notes to Financial Statements (continued)

(II) Other Financial Instruments

(4) Payable by the Company

| Category | Balance at the beginning of the year | Change during the year | Balance at the end of the year |
|------------------------|--------------------------------------|------------------------|--------------------------------|
| Payable by the Company | 123,061.04 | 103,420.62 | 226,481.66 |
| Total | 123,061.04 | 103,420.62 | 226,481.66 |

(5) Other Financial Instruments

| Category | Balance at the beginning of the year | Change during the year | Balance at the end of the year |
|--------------------------|--------------------------------------|------------------------|--------------------------------|
| Accounts receivable | 507,207,052.64 | 481,560,443.31 | 988,767,495.95 |
| Prepaid expenses | 33,132,118.55 | 8,954,970.91 | 42,087,089.46 |
| Due from related parties | 5,933,350.00 | 854,300.00 | 6,787,650.00 |
| Other | 968,519.05 | 788,231.08 | 1,756,750.13 |
| Total | 547,241,040.24 | 492,157,945.30 | 1,039,398,985.54 |

附注五、非经常性损益明细表

2022年度

(单位:人民币元)

XVI. 非经常性损益明细表

(III) 非经常性损益明细表

| 项目 | 本期发生额 | 上期发生额 | 本期发生额 | 上期发生额 |
|-----------------------|----------------|----------------|----------------|----------------|
| 1. 非流动资产处置损益 | 649,079,592.72 | 649,079,592.72 | 613,070,215.90 | 613,070,215.90 |
| 2. 计入当期损益的政府补助 | 92,882,992.81 | 92,882,992.81 | 71,256,356.09 | 71,256,356.09 |
| 3. 除上述各项之外的其他营业外收入和支出 | 741,962,585.53 | 741,962,585.53 | 684,326,571.99 | 684,326,571.99 |

1. 非流动资产处置损益

| 项目 | 本期发生额 | 上期发生额 | 本期发生额 | 上期发生额 |
|--------------|----------------|---------------|----------------|-------|
| 处置固定资产净收益 | 10,354,979.06 | | 10,354,979.06 | |
| 处置无形资产净收益 | 34,627,432.36 | 34,627,432.36 | | |
| 处置长期股权投资净收益 | 500,000.00 | | 500,000.00 | |
| 处置其他非流动资产净收益 | 203,344,031.86 | 1,322,222.01 | 204,666,253.87 | |
| 处置其他非流动资产净收益 | 51,982,515.15 | 715,222.35 | 52,697,737.50 | |
| 处置其他非流动资产净收益 | 1,832,112.13 | 301,146.25 | 2,133,258.38 | |
| 处置其他非流动资产净收益 | 27,447,511.21 | 239,581.90 | 27,687,093.11 | |
| 处置其他非流动资产净收益 | 32,626,079.15 | 230,565.10 | 32,856,644.25 | |
| 处置其他非流动资产净收益 | 2,110,854.98 | 188,216.41 | 2,299,071.39 | |
| 处置其他非流动资产净收益 | 53,500,000.00 | | 53,500,000.00 | |
| 处置其他非流动资产净收益 | 30,000,000.00 | | 30,000,000.00 | |
| 处置其他非流动资产净收益 | 10,000,000.00 | | 10,000,000.00 | |
| 处置其他非流动资产净收益 | 154,744,700.00 | | 154,744,700.00 | |
| 处置其他非流动资产净收益 | | 26,684,900.00 | 26,684,900.00 | |
| 处置其他非流动资产净收益 | | 40,954,955.16 | 40,954,955.16 | |
| 合计 | 613,070,215.90 | 70,636,809.18 | 649,079,592.72 | |

North F
F
(A 2022
RMB Y)

()
()
B
I

()

XVI. N

(III) L -t (t ,)

2. I

C

I

A

O

D

N

I

Notes to the Financial Statements
附注
F
F
2022
(A
RMB Y
)

XVI. N
()

(I)

1. R

| Item | Amount | Amount | Amount | Amount |
|------------------|----------------|----------------|----------------|----------------|
| Medical services | 337,586,514.02 | 264,978,847.50 | 365,462,139.23 | 270,930,179.07 |
| Others | 5,554,936.61 | 45,300.00 | 4,336,166.89 | 559,209.63 |
| Total | 343,141,450.63 | 265,024,147.50 | 369,798,306.12 | 271,489,388.70 |

A

| Item | Amount | Amount |
|------------------|----------------|----------------|
| Prepaid expenses | 90,612,303.06 | 93,506,118.66 |
| Others | 246,974,210.96 | 271,956,020.57 |
| Total | 337,586,514.02 | 365,462,139.23 |

2. D

T
The company has no other receivables from related parties.

() I

| Item | Amount | Amount |
|------------------|---------------|---------------|
| Interest income | 54,584,000.00 | 1,980,000.00 |
| Interest expense | -5,377,605.11 | -3,485,811.81 |
| Interest income | -18,462.42 | |
| Interest income | 714,348.18 | 6,429,189.35 |
| Total | 49,902,280.65 | 4,923,377.54 |

Definitions

| | |
|---------|--|
| AGM | 本公司 2022 年第一次股東大會 |
| A | 本公司 |
| A C | B |
| B Y H | B Y H C ., L . (北京怡寧醫院有限公司), PRC A 17, 2015, C |
| B D B | C |
| C K H | C K H C ., L . (蒼南康寧醫院有限公司), PRC J 15, 2012, C |
| CG C | C G C A 14 H K L R |
| C K P H | C K P H C ., L . (長春康林心理醫院有限公司), PRC F 16, 2016, C |
| C K H | C K H H C ., L . (淳安康寧黃鋒醫院有限公司), PRC A 16, 2020, C |
| C W K H | W K H C ., L ., PRC, H S M B H K S E (S C : 2120) |
| C S | H K L R M . GUAN W M . WANG L |

Definitions

| | |
|----------|---|
| CSRC | C S R C |
| D () | () C |
| D S () | S () C S RMB1.00 , RMB S |
| G H | W Y G H C ., L . (溫州怡寧老年醫院有限公司), PRC N 2, 2015, C |
| G | C |
| G Y H | G Y H C ., L . (冠縣怡寧醫院有限公司), PRC M 1, 2017, C |
| H S () | S () C RMB1.00 , M B H K S E |
| H C H | H C H C ., L . (杭州慈寧醫院有限公司), PRC N 18, 2017, C |
| H Y H | H Y H C ., L . (杭州怡寧醫院有限公司), PRC A 25, 2016, C O J 30, 2022, C 28% H Y H T W L L H M C ., L . (桐鄉烏鎮蓮芯蓮意健康管理有限公司). U 33% H Y H |
| H Y H | H Y P H C ., L . (荷澤怡寧精神病醫院有限公司), PRC A 6, 2017, C |
| HK\$ HKD | H K |

Definitions

H K

H K S A R

PRC

H K L R

Definitions

| | |
|------------------------------|---|
| Nanjing Yihou Hospital | Nanjing Yihou Hospital Co., Ltd. (南京怡寧醫院有限公司), a company incorporated in the PRC on July 22, 2018, with its registered office at [address] |
| Ningbo Kangning Hospital | Ningbo Kangning Hospital Co., Ltd. (寧波康寧醫院有限公司), a company incorporated in the PRC on [date] |
| Ningbo Kangning Hospital (A) | Ningbo Kangning Hospital (A) Co., Ltd. (寧波康寧醫院(股分)有限公司), a company incorporated in the PRC on September 11, 2015, with its registered office at [address] |
| Pudong Yihou Hospital | Pudong Yihou Hospital Co., Ltd. (浦江怡寧黃鋒醫院有限公司), a company incorporated in the PRC on September 3, 2018, with its registered office at [address] |
| PRC Company | People's Republic of China, including Hong Kong, Macao, and Taiwan |
| PRC Company Law | Company Law of the People's Republic of China (中華人民共和國公司法), a law enacted by the National People's Congress on December 28, 2013, and amended on March 1, 2014 (as amended) |
| Pudong Yihou Hospital (A) | Pudong Yihou Hospital (A) Co., Ltd. (浦江怡寧黃鋒醫院(股分)有限公司), a company incorporated in the PRC on November 10, 2015 |
| Qingyan Kangning Hospital | Qingyan Kangning Hospital Co., Ltd. (青田康寧醫院有限公司), a company incorporated in the PRC on April 1, 2011, with its registered office at [address] |
| Qingyan Yihou Hospital | Qingyan Yihou Hospital Co., Ltd. (衢州怡寧醫院有限公司), a company incorporated in the PRC on November 20, 2015, with its registered office at [address] |

Definitions

| | |
|--------------|--|
| T R P
R P | 31, 2022 |
| R C | B |
| RMB | PRC |
| SFO | (C 571 L H K), |
| S () | S () C RMB1.00 ,
D S () H S () |
| S () | () S () |
| S Y H | S Y H (深圳怡寧醫院, S Y
H C ., L . (深圳市怡寧醫院有限公司)), PRC
S 22, 2014, C -
H K L R |
| S R M C | B |
| | C O (C 622
H K) |
| | H K L R |
| S () | S C |
| S C | C S C PRC C
I |
| T K H | T K H C ., L . (台州康寧醫院有限公司),
PRC J 30, 2016, C -
H K L R |

Definitions

W N H W N P S H C ., L . (溫嶺南方精神疾病專科醫院有限公司), PRC J 20, 2018, C - T1 T -05.4175 -30538T (')T 0.556 -0.

